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ABSTRACT 
SMALL CELL CANCER OF THE LUNG: 
AN INITIAL EVALUATION OF THE YALE TREATMENT PROTOCOL 
David Jonathan Birnkrant 
1985 
A review of small cell cancer of the lung (SCCL) is presented, 
followed by initial results from the Yale University treatment 
protocol for SCCL. 
The review includes selected topics on the epidemiology, 
etiology, cytogenetics, cytomorphology, cells of origin, cell 
products, clinical diagnosis, staging, prognosis, and treatment of 
SCCL. The tumor emerges as one of diverse clinical behavior and 
cellular character; it remains poorly understood. Despite 
intermediate or slow doubling time, dissemination of the 
tumor—microscopic or gross—is the rule at diagnosis. Modest success 
has been achieved in treatment, allowing a small group of patients to 
go on to long-term survival (4 or 5 years), but most patients relapse 
after initial response to therapy and second-line therapy is rarely 
effective. Special attention is paid to treatment design, including 
the role of prophylactic cranial irradiation (PCI), adjuvant radiation 
therapy, and the concept of local tumor control. 
Results from the Yale University treatment protocol are 
presented. Thirty-nine evaluable patients were prospectively 
randomized to therapy with cyclophosphamide, Adriamycin, and 
vincristine (CAV) every 21 days or CAV alternating with Etoposide 

(VP-16-213). All limited disease (LD) patients underwent thoracic 
irradiation; complete responders received PCI. Eighty percent of LD 
patients achieved complete response as did 12% of extensive disease 
(ED) patients. Projected median survival ranged from 198 days for ED 
non-responders to 560 days for LD complete responders. It is too 
early to report on long-term survival. Addition of Etoposide (E) 
afforded no significant survival advantage over the CAV regimen. 
Etoposide added no significant additional toxicity; in fact, the 
percentage of patients experiencing infections requiring 
hospitalization was lower in the CAV/E group (6% vs. 33%). This may 
be the result of a smaller proportion of patients on CAV/E 
experiencing leukopenia (44% vs. 76%). 
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SMALL CELL CANCER OF THE LUNG: 
AN INITIAL EVALUATION OF THE YALE TREATMENT PROTOCOL 
PART ONE: THE BASICS 
Introduction 
Small cell cancer of the lung (SCCL) is a disease whose 
significant incidence and poor prognosis make it of major concern. 
This is especially true in a society like ours, with its increasing 
emphasis on preventive medicine and the containment of health care 
costs. The etiologic factors in the disease—tobacco smoking, 
ionizing radiation, asbestos and chemicals—make SCCL somewhat 
preventable. Treatment for SCCL is often initially effective, but 
relapse is the rule and the disease then proves resistant to second- 
line therapies. In light of the relatively poor results achieved with 
today's state-of-the-art therapy, it would be wise to direct concerted 
efforts toward prevention of SCCL.^ Unfortunately, the medical 
profession has made no successful attempt to wrest responsibility for 
such a goal from businessmen and politicians. As long as tobacco 
remains an important, heavily subsidized cash crop and images from 
Madison Avenue dictate our behavior, the individual medical 
practitioner—haranguing his patients about smoking—will remain at 
best a nagger, at worst a bore. 
This paper will emphasize the diversity in data on SCCL. Even 
the most basic aspects of the disease are poorly understood and the 
lack of an effective treatment strategy reflects that ignorance. The 

first part of the paper takes the form of a review; the second part 
presents initial data from the Yale University treatment protocol for 
SCCL. 
2 
Epidemiology and Etiology 
Lung cancer death rates have been increasing at a spectacular 
2 
rate when compared to that of other cancers. After World War II, 
lung cancer death rates for men began rising at a faster rate than 
straightline projections would have predicted. The rate curve for 
1 2 
women has followed suit for the last twenty years. ’ Projections for 
1984 show that lung cancer will be the most common cause of cancer 




Weiss has reviewed numerous studies on the incidence of SCCL. 
He reports W.E. Morton's unpublished data on SCCL rates in Portland, 
Oregon for the period 1968-1972. The disease was more frequent in men 
than women. Mean annual rates per 100,000 population were 13 for 
4 
males, 4 for females. In contrast, Annegers et al. reported a rate 
of 6/100,000 among males in rural Olmstead County, Minnesota for the 
period 1965-1974. This lower rate is consistent with the notion that 
SCCL is less common in rural areas.^ 
The median age at diagnosis in most series is about 60 years.^ 
The Philadelphia Pulmonary Research Project studied the natural 
history of lung cancer in men 45 years of age and older, each of whom 




by Weiss, show the highest incidence of disease among men 55-64 years 
of age. The study reported the highest rate of lung cancers in 
general, irrespective of subtype, in the 60- to 64-year-old age 
4 
group. In contrast, Annegers et al. found their highest incidence 
rate among men 75 years or older for the period 1965-1974. 
SCCL is generally quoted as accounting for 20-25% of all lung 
cancers.^ When the data are examined, however, the frequency of small 
cell as a percentage of all typed cancers varies widely. In Weiss’s 
3 
review, SCCL accounts for 13.7% - 39.6% of all typed lung cancers 
among men and 9.4% - 31.3% of lung cancers among women, depending on 
the study consulted. Perhaps these ranges represent differences in 
histological interpretation, or differences in incidence related to 
the population observed (the highest relative incidence figures come 
8 9 
from a study done in Iceland ). Kyriakos and Webber, reporting on 
lung cancer in young adults, have found a rate of 13% SCCL among 
patients of all ages with lung cancer at Barnes Hospital, St. Louis. 
Their review of the literature revealed that SCCL accounted for 2-38% 
of lung cancers in several large series. Interestingly, these authors 
found a slightly higher relative incidence of SCCL (24%) among younger 
patients (45 years of age or less). Kennedy^ found a remarkably high 
proportion of small cell tumors (65%) in his series of 40 lung cancers 
occurring in patients under the age of 40 in England. In contrast, 
Putnam‘S at Walter Reed Army Medical Center found 17% small cell 
tumors among 24 patients with lung cancer under the age of 40. 

4 
The male:female ratio of SCCL is generally thought to be higher 
than for other types of lung cancer, with a ratio of 3 males:1 female 
3 
reported by Morton. 
Etiological factors in SCCL include exposure to tobacco smoking, 
ionizing radiation, asbestos, chemicals, metals, and possibly air 
pollution. Pathogenesis of the disease is not well understood; the 
tumors are usually central in location and are presumed to arise, like 
squamous cell carcinoma, through chronic irritation, mucosal 
12 
denudement, and absorption of carcinogens. “ The cells of origin of 
the tumor are of great interest and will be discussed later on. 
There is probably a dose-response relationship between cigarette 
consumption and the development of SCCL. The Philadelphia Pulmonary 
13 
Neoplasm Research Project's data supported this notion. Auerbach et 
14 
al. found that small cell as a percentage of all lung cancers rose 
from 14.5% for ex-smokers progressively to 31.1% for those patients 
smoking more than two packs a day. (See Table 1.) This rise was not 
seen in other histological subtypes. Of note is the possibility that 
cessation of smoking is associated with longer survival in SCCL, even 
when patients stop at the time of diagnosis.^ 
The link between exposure to ionizing radiation and SCCL is a 
10 
strong one. Archer et al. compared rates of lung cancer and its 
subtypes among uranium miners to the rates expected for a matched 
group without radiation exposure. The authors expected to find 14.06 
respiratory cancers in their study group. Instead, 107 cases were 
recorded among the miners, 66 of which were SCCL (62%). In the 

5 
matched control group, SCCL should have accounted for 14.05% of the 
lung cancers. There was, in addition, a dose-response relationship 
found for SCCL with increasing radiation exposure. These data appear 
in Table 2. Unlike smoking, then, radiation exposure may produce a 
predominance of small cell cancers in the lung. Agreement on this 
point is not universal, however.^ 
Asbestos and chemicals have been implicated in the etiology of 
lung cancers in general. Although data on subtypes is limited, SCCL 
appears to be associated with exposure to these agents. The role of 
smoking in the carcinogenicity of asbestos is still not clear; is 
asbestos a carcinogen or a synergistic agent which promotes cancer in 
smokers? The chemicals for which there is evidence of carcinogenicity 
in humans include: "polycyclic aromatic hydrocarbons, certain metals 
3 
or their compounds, and certain simple organic chemicals." The list 
of possible carcinogens grows longer every day, but the strict 
scientific criteria needed to show causality make such proof a task 
that is pain-staking, if not impossible. 
Cytogenetics, Cytomorphology, Cells of Origin, 
and Cell Products 
The basis of understanding the small cell tumor lies in an 
understanding of its component cells. One approach to these cells is 




Wurster-Hill and Maurer studied the chromosomes of patients' 
SCCL tumors using direct bone marrow preparations and trypsin-Giemsa 
banding. Chromosome number and structural aberrations (markers) were 
frequent and highly variable. Chromosome number (ploidy, DNA index) 
in untreated patients ranged from hypodiploid to polyploid with the 
latter most common (the chromosome count was typically in the 
80's). A structural abnormality of chromosome #1 was found in 14 of 
the 18 patients with karyotypic abnormalities (total patients = 26). 
But very few markers were common to two or more patients and the 
consistency of given markers among the cells from one patient was 
usually poor. The presence of cells with different abnormalities of 
chromosome number in the same patient (e.g., diploid and polyploid) 
18 
was discovered. Vindelov et al. found that ploidy in their SCCL 
tumor cells could be grouped into near-diploid, near-triploid, and 
near-tetraploid values. Each of five patients was found to have two 
clones with different chromosome number in a single metastasis (17% of 
the total patients). The authors view this as evidence that SCCL, at 
least for some patients, is not monoclonal. That is: new cell lines 
evolve from the original tumor. These cell lines may have 
characteristics (clinical, biochemical) that are entirely different 
from those of the original tumor. The heterogeneity of the SCCL 
tumor—a concept emphasized in this paper—may lie in the evolution of 
more than one cell line from the original tumor. 
19 
Whang-Peng et al. found two distinct stem lines in 2 of their 
12 cell lines cultured from human small cell lung cancer tissue. 

7 
These authors describe a consistent, acquired chromosomal 
abnormality—a deletion in the short arm of chromosome #3—present 
both in SCCL cell lines and in fresh clinical specimens cultured for 2 
days in a serum-free medium. Chromosome studies of other types of 
neoplasms have not shown a specific abnormality of chromosome #3. The 
data of Wurster-Hill and Maurer (abnormality of chromosome #1) do not 
fit easily into the scheme of Whang-Peng et al.; an explanation of the 
discrepancies awaits elucidation. Whang-Peng et al. appear to have 
found a specific, acquired somatic cell defect (deletion 3p, 14-23) 
associated with continued replication of SCCL tumor cells. If this 
holds true, the diagnosis and treatment of SCCL will be 
aided—especially if the function of the genes present in the region 
of chromosome #3 where the deletion was found can be understood. 
Another approach to the cells of the tumor is to ask: where does 
SCCL arise from? That is, which cells in the lung first acquire the 
chromosomal abnormalities, due to exposure to carcinogens, which lead 
to the growth of a tumor? 
20 
Hattori et al. studied 24 cases of oat-cell (small cell) 
carcinoma of the lung and four cases of bronchial carcinoid tumor both 
under the electron microscope and biochemically. They found that SCCL 
tumor cells were characterized by the presence of neurosecretory-type 
granules (NSGs) of 800-2000 Angstroms, almost identical to but 
somewhat smaller than the NSGs found in 4 samples of bronchial 
carcinoid tumor. NSGs were not found in 139 samples of other types of 
lung tumors studied. Serum serotonin level was elevated in 13 of 20 

8 
small cell cases and the degree of elevation seemed to correlate with 
the number of NSGs present in the tumor cells. Serotonin level in 
tumor tissue was elevated in 7 of 12 cases of SCCL but in only 1 of 4 
cases of bronchial carcinoid tumor. In 5 of 7 cases of SCCL, both 
serotonin and ACTH were elevated in tumor tissue samples. Other types 
of lung cancer, which lacked NSGs, showed no elevation of serotonin 
activity with the exception of one case of squamous cell carcinoma 
(and one case of pleurisy due to collagen vascular disease). The 
authors noted that the NSGs they found in bronchial carcinoid and SCCL 
were identical to those which had been previously described by Bensch 
21 
et al. in the Kulchitsky-type cells in bronchial mucus glands. 
Hattori et al. thus concluded that "oat-cell carcinoma is a special 
type of lung tumor producing neurosecretory-type granules and a highly 
malignant variant of bronchial carcinoid tumor which is originated 
from neurosecretory-type cell (Kulchitsky-type cell) found in 
20 
bronchial glands." This is a remarkable statement, for the authors 
have found an association between electron microscopic characteristics 
of the tumor (NSGs) and tumor products (serotonin, ACTH) known to have 
22 
clinical significance as ectopic hormone products of SCCL tumors. 
Moreover, the ultrastructure of the tumor cells has provided a clue to 
cell origin: the Kulchitsky-type cells of bronchial glands. The 
latter can produce serotonin from tryptophan and 5-hydroxy-tryptophan, 
which means they fit into Pearse's conception of an APUD (Amine 
23 
Precursor Uptake and Decarboxylation) cell."- APUD origin would, in 
turn, imply a way of attacking the embryological lineage of SCCL's 

9 
cells of origin and relate SCCL to other cells of APUD origin in the 
body. In fact, the above associations reach beyond our ability to 
24 
apply them. Indeed, Hattori et al. examined the cytomorphology of 
SCCL tumors in relation to response to therapy in an article published 
five years after the one already discussed. Surprisingly, although 
almost all SCCL tumor cells were found to contain NSGs, the cells from 
tumors which did not respond to combination chemotherapy showed few or 
no NSGs. Some of the tissue specimens used in the study were obtained 
from autopsy material, and it is possible that chemotherapy affected 
the cell structure. Alternatively, a cell line without NSGs could 
have arisen from the original tumor. Still, the lack of NSGs in the 
non-responder group shakes the foundation of attempts to characterize 
SCCL at an ultrastructural level in a way that is consistent with the 
presumed cells of origin. 
25 
Tischler notes that the APUD concept has been elucidated and 
revised since its initial introduction. APUD cells are now known to 
occur in two distributions in the lung: as scattered Kulchitsky-like 
cells and as organized groups of cells called neuroepithelial bodies. 
Both occur in close proximity to nerve endings. The secretory 
products and physiological role of APUD cells in the lung are 
obscure. While the APUD concept may explain the source of some of the 
hormones SCCL tumors produce, cytogenetic abnormalities—"derepression 





Still, APUD has been used as a window to the study of SCCL's 
ectopic hormones. A wide variety of such hormones have been 
identified and include ACTH, ADH, calcitonin, glucagon, HCG, 
18 22 27 
serotonin, PTH, and estradiol. ’ ’ The frequency of ectopic 
hormone production by small cell tumors is not known; it is clear, 
however, that clinically apparent syndromes that can be traced to 
these hormones are much rarer than production of the hormones 
themselves. Thus, while more than 50% of patients may have abnormally 
high levels of hormones such as ACTH, ADH and calcitonin, clinical 
syndromes such as SIADH or Cushing's syndrome appear to occur in less 
28 
than 10% of patients. Richardson et al. point out that the identity 
of these tumor-produced "ectopic hormones" is not really known; they 
may or may not be identical to "normal" hormones and radioimmunoassays 
. 28 
of these substances may be neither truly sensitive nor specific. 
29 
Despite these caveats, Science marches on. Baylin and Gazdar 
have measured biochemical indices in SCCL with established 
relationships to APUD cells outside the lung. These include L-dopa 
decarboxylase (central to the APUD concept—it converts precursor 
amino acids into their corresponding amines); and calcitonin (produced 
by the APUD tumor medullary thyroid carcinoma). They also measured 
histaminase and beta-endorphin, neither of which is specific to APUD 
cell activity; still, both substances are thought to be involved in 
hormone production by cancers. The authors found that the biochemical 
parameters studied were not specific to SCCL and that there was great 
heterogeneity of findings between different patients with SCCL, among 

11 
different lesion sites (primary vs. metastatic) in the same patient 
with SCCL, and even within individual SCCL lesions. These data are 
viewed as a reflection of heterogeneous cell populations all of which 
are grouped together under the clinical term "small cell lung 
cancer." The authors noted that quantitatively, however, their 
endocrine parameters tended to group more with SCCL than with other 
lung tumors. 
An attempt has been made to find tumor products which will prove 
to be specific markers of SCCL, whose concentrations are proportional 
to tumor burden, and which are present in enough patients to make 
measurement worthwhile. Three such newly described products are 
bombesin, the BB isoenzyme of creatine kinase (CK-BB), and 
neuron-specific enolase (NSE). I will describe a study of NSE as an 
example. 
30 
Carney et al. studied serum NSE levels at diagnosis in 94 
patients with SCCL. The levels were repeated during and after 
therapy. Sixty-nine percent of all patients had a serum NSE level 
more than 3 S.D. above control, including 87% of the patients with 
extensive-stage disease (ED). Mean serum NSE was significantly higher 
in patients with ED than in those with limited-stage disease. In 20 
of 21 patients, all of whom had elevated NSE levels at diagnosis, 
serum NSE fell significantly as the patients responded to 
chemotherapy. In the one patient whose level remained unchanged, no 
response to therapy was achieved and the disease progressed. The NSE 




Serial NSE measurements showed a good correlation between 
clinical condition and the level of the marker. For example, in 9 
patients with raised NSE levels on diagnosis the levels fell to near 
normal range with therapy then rose again when the patients relapsed. 
NSE has been identified in all cell lines of SCCL tested; it has not 
been found in substantial amounts outside central and peripheral 
nervous system tissue, findings consonant with the fact that APUD 
cells and neurons tend to express much of the same genetic 
25 
information—they are "neuro-endocrine programmed." NSE thus has 
the potential to be a useful marker for SCCL; immunohistochemical 
staining of lung tissue for NSE might someday help in making 
pathological diagnoses. 
A recent cytomorphological finding deserves mention. SCCL cells 
from biopsies and derived cell lines were shown to contain 
31 
neurofilament-type intermediate filaments. Since the expression of 
these filaments is tissue type specific and thought to be unchanged 
after malignant transformation, another line of approach to the APUD 
origin and diagnosis of SCCL may have been uncovered. 
Despite the uncertainties described, a picture begins to emerge 
of the cells that make up SCCL tumors. At a cytogenetic level, they 
are characterized by variable numbers of chromosomes (ploidy) and a 
specific acquired deletion of the short arm of chromosome #3—3p 
(14-23). The cells contain neurosecretory granules and appear to be 
of APUD origin. Although SCCL cells express a variety of biochemical 

13 
products, including certain hormones which account for clinical 
syndromes associated with the disease, truly useful biochemical 
markers for SCCL, which combine sensitivity and specificity, may 
include neuron-specific enolase (NSE); bombesin (BN); and the BB 
isoenzyme of creatine kinase (CK-BB). Finally, the idea that SCCL is a 
collection of multiple cell lines, both in individual tumors and 
between patients, is supported by the variety of tumor products and 
their levels expressed by cells from single tumor sites; by cells 
taken from primary vs. metastatic sites; and by cells from tumors 
found in different patients. The notion of multiple cell lines is 
further supported by the variable number of chromosomes (ploidy) found 
18 
by Vindelov et al. in some tumor samples from a single metastatic 
24 
site and by Hattori et al.'s finding of decreased or absent 
neurosecretory granules in the cells of tumors unresponsive to 
chemotherapy. The characteristics of SCCL have been further 
elucidated by recent studies which build on the picture above. 
Tumor cell chromosome number was recently examined in relation to 
32 
treatment response by a group at M.D. Anderson Hospital. They found 
a DNA index of 0.70 to 2.09 (1.0=diploid) among 126 pre-treatment 
specimens. Six percent of the cases had bi-clonal stem lines. 
Hypodiploid tumors had decreased percent S-phase cells (reflecting 
lesser proliferative activity). These tumors showed slower drug 
response, but the response was more prolonged with resultant better 
survival when compared to hyperdiploid tetraploid tumors characterized 
by high % S-phase cells. Percent survival at more than 60 weeks could 

14 
be stratified by DNA index in a significant way, raising the 
possibility that chromosome number and proliferative activity analysis 
may one day be used as prognostic criteria. The presence of more than 
one cell line in some tumors was again confirmed. 
The use of monoclonal antibodies (MoAbs) may prove to be a useful 
method whereby antigenic expression—and thus, indirectly, the tumor 
genome—can be studied. Implications for future treatment design are 
numerous and include the attachment of anti-tumor drugs to MoAbs, 
creating a highly specific tumoricidal agent. 
Groups at the NCI have published numerous abstracts in the last 
two years reporting on studies in which MoAbs have been applied. 
Considerable antigenic heterogeneity has been found within individual 
SCCL tumors, between tumor lines, and, to a more limited degree, 
33 
between clonally related lines. SCCL is thus proving to be 
heterogeneous in a way that challenges our understanding of cellular 
behavior at the level of molecular genetics. Relative homogeneity has 
been found in cell lines from different metastatic sites in the same 
patient. This homogeneity was especially evident when numerous 
characteristics of the cells were examined simultaneously: the 
biomarkers dopa decarboxylase (DDC) and bombesin (BN), DNA index, and 
34 
three forms of antigenic expression (using MoAbs). Still, the 
heterogeneity of antigen expression in tumor tissue and the poor 
specificity of "tumor" antigens—i.e., their diverse distribution in 
normal tissue—may cause considerable difficulty in the clinical 
35 
application of MoAbs. 

15 
A finding which may prove to be specific is that of HLA-A,B,C, 
and beta-2 microglobulin deficiencies on the cell surfaces of human 
SCCL lines, detected by MoAbs. Thusfar, non-SCCL lines have been 
strongly positive for these structural markers. 
36,37 
38 39 
Two exceptionally interesting reports from the NCI ’ have 
appeared recently which illustrate our ability to study SCCL at a 
cellular level through the use of biochemical markers, continuous cell 
lines, and measurements of radiosensitivity and tumorogenicity. The 
authors report two major subgroups of SCCL: a classic form, which 
expresses DDC, BN, NSE and CK-BB; and a variant form, which has a 
faster doubling time and shorter latent period to tumor induction in 
nude mice than the classic form. The variant form is radioresistant, 
nor does it produce DDC or BN in appreciable quantities. It has 
metabolic features which distinguish it from the classic form: 
despite the presence of CK-BB, the product whose formation that enzyme 
catalyzes (phosphocreatine) is not present in classic cell lines. 
Phosphocreatine isn’t present in non-SCCL lines, but is present in the 
variant cell lines. 
The possibility that there are two major subgroups of SCCL—one 
clinically aggressive, resistant to treatment, and lacking the 
characteristic APUD enzyme (DDC)—is reminiscent of the findings of 
2 A 
Hattori et al. Recall that those authors reported on the lack of 
neurosecretory granules (NSGs) in a group of tumors resistant to 
chemotherapy. Are Hattori's resistant tumors composed of cells from 
the NCI's variant subgroup? The absence of DDC in a tumor one would 
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expect to be clinically aggressive (the SCCL variant) is like the 
absence of NSGs in tumors proven to be therapy-resistant: basic APUD 
characteristics are lacking. The usefulness of APUD characteristics 
in understanding SCCL is not clear. The APUD origin of some cell 
lines becomes questionable. Perhaps tumor cells lacking NSGs and cell 
lines with characteristics of the variant subgroup are highly 
aggressive subpopulations of cells which have evolved from the 
original, more indolent APUD-derived tumor. The concept of classic 
and variant cell lines and the presence of more than one cell line in 
32 
a tumor also brings to mind the report from M.D. Anderson which 
stratified tumor aggressivity by chromosome ploidy and proliferative 
activity. 
Cytogenetic study of the classic and variant cell lines— 
evaluating chromosome number and seeking the deletion in chromosome #3 
19 
associated with SCCL —as well as cytomorphological study, with a 
special interest in neurosecretory granules, may prove fruitful. 
Clearly, researchers are only beginning to explore the cellular basis 
of SCCL's clinical behaviors. 
Clinical Diagnosis 
Cohen and Matthews,^ Matthews and Hirsch^ and Matthews ^ have 
reviewed the radiographic, clinical, and pathological presentations of 
SCCL. 
On X-ray, SCCL usually appears as a central mass. Because the 
tumor metastasizes early, hilar node involvement is common, with or 
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without mediastinal widening on presentation (64%). Post¬ 
obstructive pneumonitis, atelectasis, and pleural effusion (due to 
lymphatic blockage) may be present. Less commonly, a peripheral tumor 
mass is seen on presentation (19%). Very rarely, the patient presents 
with a central tumor mass and no obvious nodes (3%). The lesion must 
be distinguished from epidermoid (squamous cell) carcinoma, which also 
presents as a central lesion. But epidermoid lesions are rarely 
associated with mediastinal adenopathy or widening as evident as that 
in SCCL. Moreover, SCCL tumors demonstrate central cavitation less 
frequently than squamous cell lesions. 
While the pathogenesis of SCCL and epidermoid cancer is probably 
similar, there are numerous differences in gross pathology. 
Epidermoid tumors are often bulky, polypoid, obstructive intraluminal 
growths, with a friable consistency, with or without central 
cavitation and liquefaction necrosis. SCCL, in contrast, tends to 
form submucosal plaques that spread to involve central 
structures: the trachea, mainstem bronchi, and the bronchial, hilar, 
and mediastinal lymph nodes. If the superior vena cava is invaded, it 
can be thrombosed, causing SVC syndrome. (SVC syndrome may also arise 
secondary to compression.) SCCL tumors have a glossy grey-white cut 
surface that is frequently hemorrhagic and necrotic—but central 
cavitation is rare. 
Pathological classification of SCCL is based on light 
microscopy. In 1977, the World Health Organization revised their 
classification system based on a decade of study. The subtypes now 
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used include lymphocyte-like or oat cell (#21); intermediate forms 
(fusiform, polygonal, "other"—#22); and combined (oat cell with a 
definite component of squamous cell or adenocarcinoma). 
The nuclear detail of small cell—its fine or coarse stippled 
pattern of nuclear chromatin and small, indistinct nucleoli—is highly 
characteristic. Cytoplasm is usually scanty or may appear to be 
absent. Cells are arranged in a loosely cohesive but clustered 
pattern, forming cords, sheets, or pseudorosettes (cuffing around 
blood vessels). 
There are numerous problems that arise in diagnosing SCCL, as 
40 
reviewed by Matthews and Hirsch. These include inadequacy of biopsy 
material (biopsy samples that are too small, bronchial washings or 
sputa of equivocal cytology); crushing of tissues, resulting in 
overinterpretation of malignancy; and improper tissue processing, with 
resultant artifacts. The authors contributed to two interobserver 
studies designed to identify problems and assess reliability in SCCL 
42 43 
diagnosis. ’ They found unanimity or "near unanimity" (7 of 8 
pathologists) in the diagnosis of SCCL in over 90% of the tumors 
studied. The consistency of subtyping of SCCL tumors according to the 
1977 WHO criteria was assessed in one of the studies. Unanimity among 
3 pathologists was achieved in only 54% of the cases. This is a 
remarkable figure, for it raises doubts about all studies designed to 
characterize SCCL subtypes (e.g., the response of different subtypes 
to therapy—a topic to be discussed later). 
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The great majority of patients with SCCL are symptomatic at 
presentation. Cough is a common symptom, referable to the primary 
tumor. Chest pain, dyspnea, symptoms of pneumonitis (due to 
obstruction or compression), wheeze and hemoptysis may occur. (See 
12 44 
Table 3.) ’ Mediastinal extension of the tumor results in 
hoarseness or SVC syndrome, the former secondary to involvement of the 
recurrent laryngeal nerve (usually on the left, where its course is 
longer). SVC syndrome tends to be associated with right lung tumors, 
since the superior vena cava passes through the chest on the right. 
Early, widespread metastases are the hallmark of SCCL and 
45 
contribute to its symptomatology. Livingston et al., in their 
series of 375 patients, found liver to be the metastatic site most 
often involved in extensive-disease patients, followed closely by 
bone; then, bone marrow, brain, skin/soft tissue/nodes, and pleural 
45 
effusion. (See Table 4.) Thirty-seven percent of these patients 
had involvement of more than one metastatic site, in contrast to 49% 
46 
in a study of 106 patients at the NCI. The significant metastatic 
sites, in terms of symptomatology, are bone and brain, causing pain 
and neurological complaints, respectively. Although cardiac 
involvement is rarely mentioned in clinical series, 20-25% of SCCL 
patients have been reported to have cardiac metastases at 
12,14 
autopsy. ’ (See Table 4.) Such involvement can result in signs and 
symptoms of heart failure, EKG changes, even tamponade. Adriamycin, 
commonly used in treatment protocols for SCCL, has cardiotoxic side 
effects; thus, ejection fractions are routinely computed at the start 
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of therapy. Still, one wonders what implications subclinical cardiac 
involvement might have with respect to treatment complications. 
The existence of clinical syndromes related to ectopic hormone 
production by SCCL tumors has already been mentioned. All are rare. 
SIADH, reported in 5-10% of most series, seems to occur most 
frequently in association with SCCL when the cause of SIADH is 
22 
neoplastic. CNS manifestations predominate in symptomatic patients 
and may include seizures, disorders of consciousness, and 
extrapyramidal signs. The patient is unable to excrete a maximally 
dilute urine when presented with a water load and such testing can 
uncover many subclinical cases. Fluid restriction helps correct the 
hyponatremia, but chemotherapy is the definitive approach. 
Ectopic ACTH production is clinically significant in 3-7% of 
22 
patients with SCCL. Numerous tumors thought to be of APUD origin 
make the hormone. Symptomatic patients rarely present with the 
classic features of Cushing's syndrome—instead, weight loss, severe 
weakness, glucose intolerance, edema and/or hypertension are more 
likely presentations of their hypercortisolism. The metabolic 
complications of symptomatic ACTH overproduction can be severe and 
22 
management is difficult, although Greco et al. report early evidence 
that combination chemotherapy can be effective. 
Paraneoplastic syndromes other than ectopic hormone production 
have been found to be associated with SCCL. Possible etiologies of 
these syndromes include viral agents, autoimmune phenomena, and 
humoral substances elaborated by the tumor.^ 
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Eaton-Lambert syndrome is associated with SCCL more often than 
22 
with other diseases. It is an unusual clinical entity, 
characterized by the dichotomous findings of proximal muscle weakness 
with difficulty walking coupled with facilitation of muscular 
potentials on repeated stimulation. Thus, the patient's grip may 
become stronger and stronger during testing. The syndrome tends to 
occur among male patients over 40 years of age and seems to respond to 
cytotoxic therapy. Should chemotherapy fail, guanidine may be 
22 
effective by causing increased release of anticholinesterases. The 
electromyogram is diagnostic. 
A final syndrome requiring mention is paraneoplastic 
22 
encephalopathy. This is thought to be the cause of death in two 
patients in the present study. Clinically, the syndrome may involve 
the cerebrum, brainstem, optic nerves, and cerebellum. Pathologic 
lesions are generally found in all these regions, although involvement 
of one area may dominate the clinical picture. Dementia is the most 
common manifestation of cerebral involvement. Radiologic studies are 
normal; the CSF may show an elevated protein level; the E<EG is often 
slow and diffuse. 
Staging and Prognosis 
There is a TNM (tumor-nodes-metastases) staging system for SCCL 
but its use, until recently, had fallen out of favor. The TNM system 
is surgically-oriented and poor therapeutic results have been achieved 
using surgery alone. TNM was viewed as prognostically useless. More 
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recently, however, interest in surgery as an adjuvant therapy (part of 
a multimodal therapeutic approach) has been revived and the TNM system 
may yet take its place as a standard method of staging. (See the 
section on treatment.) Still, the system of the Veterans 
Administration Lung Cancer Study Group remains the one employed in 
almost all current studies. It divides patients into limited-stage 
(LD) and extensive-stage (ED) disease groups. LD is defined as tumor 
confined to one hemithorax with or without mediastinal 
lymphadenopathy, with or without ipsilateral supraclavicular node 
involvement. The tumor must fit within a single radiation therapy 
portal. Tumor beyond these confines is defined as extensive 
47 
disease. 
In general, two-thirds of all patients present with ED; one-third 
5 48 49 48 
with LD. ’ ’ Ihde and Hansen have pointed out that, with very 
thorough diagnostic work-ups, more patients with metastatic disease 
not easily detectable are placed in the ED group. When this is done, 
survival data for the individual ED and LD groups may appear improved, 
since a group of relatively "healthy" ED patients is created by 
removing a group of relatively "sick" LD patients. Overall survival 
(ED + LD) does not change. The truth of this observation must be 
supplemented by the observation that, despite the sophistication of 
the technology available to the physician determined to uncover the 
most retiring metastasis, test results are often equivocal. It is not 
clear whether or not to include certain patients in the ED group and 
they may be given the "benefit of the doubt"—identified as patients 
* 
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with limited disease so that they might enter the LD treatment group. 
When this happens, the survival of the ED group presumably goes up and 
that of the LD group goes down. Again, overall survival remains 
unchanged. 
Involvement of certain metastatic sites has been found to have 
prognostic significance. More fundamentally, extent of disease has 
strong prognostic implications. Staging procedures in SCCL must be 
designed with these facts in mind. Diagnostic modalities must be 
selected for their combination of sensitivity and specificity. 
Chest X-ray remains the basic method by which intrathoracic 
disease is evaluated. However, fiberoptic bronchoscopy is a very 
useful tool—it allows diagnosis by biopsy or bronchial washings and 
can detect small lesions. The bronchoscope is used routinely at some 
centers to document complete response to therapy. 
CT scans of the chest are less widely used, although they provide 
a better sense of tumor volume. Some note that the CT scan's 
sensitivity is not matched by its specificity in detecting malignant 
pulmonary nodules when compared to conventional linear 
tomography. Others point to the relative inaccuracy of CT scans in 
diagnosing disease in the middle mediastinum when compared to staging 
mediastinoscopy or thoracotomy.^ Still, CT provides useful 
51,52 
information not obtained with conventional radiography. 
Both mediastinosocopy and CT of the chest may take on a more 
important role in initial staging in the future. The reason for this 
is the resurgence of interest in TNM staging to evaluate adjuvant 
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surgery for early control of intrathoracic tumor mass. Surgery aside, 
data is accumulating that would indicate a survival advantage for 
patients with smaller presenting tumors in the chest. A group in 
53 
England found a higher incidence of complete response and a survival 
advantage for patients with intrathoracic tumors whose total 
2 54 
cross-sectional was area less than 30 cm on CT. A Toronto group 
reported a significant survival advantage for limited disease patients 
without superior mediastinal node involvement as diagnosed by 
mediastinoscopy or roentgenographic appearance—i.e., patients with 
so-called "very limited" disease, which is potentially resectable. 
These two studies illustrate the potential use of CT and/or 
mediastinoscopy in evaluation of chest tumor extent. Such information 
could be useful for treatment and/or prognosis. 
Bone and bone marrow are common sites of metastatic spread. It 
seems important to perform both bone marrow biopsy and aspiration^ as 
56 
well as bone scan if extent of disease is to be assessed, for the 
procedures complement each other to some extent. The prognostic 
57 
significance of these sites of involvement is unclear, however. Two 
recent studies found bone marrow involvement to be a negative 
58 59 
prognostic factor; ’ a third report found no prognostic 
significance. ^ A study from the Finsen Institute^ identified a 
group with an especially poor prognosis: patients with bone marrow 
metastases and thrombocytopenia. In any case, bone scan and bone 
marrow biopsy and aspiration remain standard procedures in staging 
48 
SCCL. Ihde and Hansen have reported worsening of the bone scan 
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during overall disease remission in a minority of patients. 
Liver metastases appear to be a negative prognostic factor. 
46 61 59 
Groups at the NCI ’ and Toronto have found liver involvement to 
bode ill and the level of interest in accurate diagnosis of liver 
metastases supports the wide acceptance of this notion. 
A variety of techniques may be used to evaluate the liver, 
including liver function tests, radionuclide scanning, CT, 
peritoneoscopy with biopsy, percutaneous biopsy, and ultrasonography 
with fine needle aspiration. Liver-spleen radionuclide scan remains 
the mainstay of current staging. Although this modality has been 
maligned, it remains a reliable, available, relatively inexpensive, 
62 
non-invasive diagnostic tool in SCCL. At the NCI, peritoneoscopy 
with liver biopsy was found to be the most sensitive diagnostic 
method, but an algorithm combining radionuclide scan with liver 
function tests was highly accurate while remaining non-invasive.^ A 
63 
recent study from the Finsen Institute reported ultrasonography with 
fine needle aspiration to be more accurate than peritoneoscopy. The 
ultrasound technique was also ’’less invasive"—but the number of 
patients studied was small. 
Whether or not prophylactic irradiation should be employed to 
avoid CNS metastases in patients with SCCL is a controversial topic. 
Less controversial is the prognostic significance of CNS involvement 
and how to diagnose it. 
Brain metastases are present in approximately 10% of patients 
48 
with SCCL at diagnosis and in 30-65% of patients at autopsy. As 
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therapy improves and patients with SCCL live longer, they accumulate 
greater risk for developing this complication. 
Both the NCI^ and Toronto"^ groups found brain metastases to be 
a negative prognostic factor, but this result has not been 
invariable. Diagnosis can be made by radionuclide scan or CT of the 
head. CT scans are thought to be superior,^ uncovering lesions 
64 
before they become symptomatic and allowing accurate staging. 
A current set of recommendations for restaging of patients 
thought to have achieved clinical response is presented in Table 
5.5 The argument that restaging should be effected with as much care 
as initial staging is a good one since any metastasis large enough to 
be clinically detectable is of great significance. Perhaps someday 
biomarkers already described (e.g., bombesin, neuron-specific enolase) 
will become standard indicators of subtler disease. 
What factors can be said to have prognostic significance in SCCL? 
Performance status—a numerical estimate of a patient's ability to go 
about his daily routine with or without symptoms—and stage of disease 
(limited vs. extensive), predominate in most studies of significant 
48 59 
prognostic factors. ’ In fact, the International Association for 
the Study of Lung Cancer feels it is no longer necessary to 
demonstrate the superior survival of patients with LD in current 
chemotherapy treatment reports.^ Still, significantly improved 
4-6 
survival for LD patients is not a universal finding. Data already 
mentioned indicate that small intrathoracic tumor area and a finding 




prognostic advantage. ’ Patients who have failed a previous 
chemotherapeutic protocol invariably have a bad prognosis on 
48 
second-line therapy. 
The following are of less certain significance. Weight loss on 
presentation (0-10%) has been found to be associated with 
66 
significantly decreased median survival, as has multiple metastatic 
46 
sites (one vs. two vs. three or more). Age of 55 years of more has 
been associated with decreased response rates and shorter survival in 
patients not achieving complete response.^ 
Numerous laboratory parameters may be useful as prognostic 
indicators; carcinoembryonic antigen (CEA) has been reported to be an 
independent prognostic factor, ^ as has LDH.~^’^ The feasibility of 
using an objective prognostic index based on laboratory parameters at 
diagnosis to replace subjective performance status assessment is under 
study. At the NCI, ^ albumin and hemoglobin were found to be the most 
influential prognostic factors in survival. 
The fact that, of the various metastatic sites, CNS and liver are 
the most likely to have prognostic significance has already been 
discussed. 
Finally, the prognostic significance of the various subtypes of 
SCCL remains unclear. The VA Lung Groups reported better survival 
for patients with lymphocyte-like (classic, oat-cell) 
vs. intermediate-type disease. This held true for patients within the 
extensive disease group, but not the limited disease group, when 
72 
analyzed separately. In contrast, a large NCI study ~ found no 
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clinically significant differences among the subtypes. A recent 
community hospital study indicates that lymphocyte-like SCCL may be 
73a 
associated with better 2 year survival. 
The pathology panel of the International Association for the 
Study of Lung Cancer is in the process of proposing a revision of the 
73b 
current WHO histological classification system for SCCL. The 
"combined" subgroup would remain; however, "oat cell" and 
"intermediate" subtypes would be classified together in the new 
"classic small cell" subgroup. Another new subgroup would be 
created; "small cell-large cell," in which there is an admixture of 
classic small cells with large cells having open nuclei and prominent 
eosinophilic nucleoli. 
73 b 
Dr. Raymond Yesner has reported, in a personal communication, 
that the new classification system is based on the belief that 
polygonal and fusiform cell types—currently grouped in the 
intermediate subtype—show no significant clinical, biological, or 
ultrastructural differences from classic oat cells. The VA Lung Group 
study7^ as reported earlier in this paper, found a survival advantage 
for oat cell over intermediate-type disease. It turns out that this 
group, unlike investigators who found no such survival advantage, 
included in the intermediate subtype only tumors with a mixture of 
classic small cells and large cells—not tumors of polygonal and 
fusiform cells, which they grouped with classic oat cell tumors. The 
proposed classification system is based on the belief that tumors of 
the small cell-large cell subgroup carry a graver prognosis than those 
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of the classic small cell subgroup. 
Finally, the new small cell-large cell subgroup is thought to be 
identical to the in vitro "variant" cell line described earlier in 
38 39 
this paper based on reports from the NCI. ’ The variant cell line 
is relatively resistant to radiation and chemotherapy and has a large 
cell appearance, but produces some characteristic SCCL biomarkers. 
Similarly, the classic small cell subgroup is felt to have its in 
vitro equivalent in the NCI's "classic" subclass. 
Table 6 presents a summary of prognostic factors. 

PART TWO: TREATMENT 
Overview 
A better theoretical grasp of cancer in general now permits 
clinicians to treat SCCL with a modest degree of success. As the 
characteristics of the tumor become better understood, the limitations 
of current therapy become painfully clear. Will the treatment 
breakthrough come from the slow evolution of rational therapeutic 
design or through a fortuitous discovery? It is unlikely that 
stepwise investigation will cure SCCL in the near future; and, given 
the cost-conscious environment of present-day cancer research, the 
prospect of a serendipitous discovery is better thought of as a 
fantasy than a hope. 
In order to treat SCCL and to evaluate properly its response to 
treatment, the growth characteristics of the tumor need to be known. 
Two basic approaches exist: measures of clinical doubling time made 
by estimating tumor volume changes on chest radiographs over time; and 
in vitro studies of tumor cells. Tritiated thymidine uptake by SCCL 
cells allows calculation of the labeling index (LI)—the fraction of 
labeled tumor cells among all cells counted. LI reflects the rate of 
cell production by the tumor—it measures the fraction of cells 
actively synthesizing DNA. 
SCCL responds well—initially—to treatment with radiation 
73c 
therapy (which acts on dividing cells) and to treatment with agents 




(which is probably cycle-dependent). Intuitively, one would 
therefore expect SCCL to be a rapidly dividing tumor—one with a high 
LI and short doubling time as measured in clinical studies. 
Initial results were consistent with this view.^ For a while, 
researchers took a value of about one month as the doubling time of 
small cell tumors. Based on this assumption, the period of risk—the 
amount of time for regrowth from a single cell to clinical 
recurrence—was thought to be about two years. 
Two years became a magical interval, synonymous with long-term 
survival^^ and, perhaps, cure. This view was consistent with 
clinical impression, doubling time data, and the finding that SCCL had 
a higher median LI than other solid tumors (except Burkitt's 
78 
lymphoma). Although it has since become clear that two year 
survival is of limited value, it remains, for many, an important 
criterion. A review article from 1982 states that "many patients who 
survive alive and disease-free for 2 years, remain 
79 
disease-free." The reference given, from 1979, was employed 
i 77 
above. 
In 1978, a group at the NCI reported a median doubling time of 
77 days (range: 25-160 days) among their 12 cases of SCCL. Most 
tumors were felt to have demonstrated relatively intermediate or long 
doubling times. Assuming that the range of lxlO^3 to 1x10^ cells is 
clinically significant, the authors used the median doubling time of 
77 days to project that therapy leaving a tumor burden of 1x10 cells 
would not present as a clinical relapse for at least two years; 
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therapy destroying all but one cell would produce an interval of risk 
lasting 4-5 years. 
The above projections may not be entirely accurate. First, the 
range of tumor doubling times must be taken into account. Second, 
treatment may change the cell kinetic characteristics of SCCL 
78 
tumors; there is good evidence to support biochemical and 
81 82 
histological changes in tumors after therapy. ’ Still, 4 or 5 year 
survival is probably more accurately synonymous with long-term 
survival if cure is implied. Clinical evidence has accumulated to 
support this notion in the form of late relapses. 
Such evidence has been available for a number of years. The 
83 
NCI-International Association for the Study of Lung Cancer report 
which appeared in 1980 studied patients who survived more than 2.5 
years. Recurrent disease was noted in 21 of 96 patients: 8 patients 
died 30-33 months after diagnosis; one was alive, with disease, at 34 
months; recurrence was detected in 10 other patients after 36-51 
months; and two patients treated by surgery alone succumbed to 
recurrent disease at 8 and 9 years, respectively. 
Recently, data from cooperative and single institutions have been 
84 
gathered on late relapses. The NCI reported that 8 of 28 patients 
who had been disease-free at 30 months relapsed with SCCL (median: 54 
months from diagnosis; range: 31-74 months) after follow-up of 5-10 
years. The group at M.D. Anderson Hospital reviewed patients 
surviving 3 years or more. Eleven of 43 such patients relapsed 




years. Livingston, reporting for the Southwest Oncology Group, 
looked at 17 patients who survived 5 years or more in a single study 
(13% of those entered). Five late deaths were due to recurrent tumor 
(onset: 33-73 months from treatment). 
87 
As early as 1978, Greco et al. published a paper in which the 
notion that 2 year survival might not represent cure was clearly 
expressed. The existence of "late recurrences" was recognized. 
Before discussing treatment modalities: What is the natural 
history of SCCL? The median length of survival of untreated patients 
with SCCL is generally quoted as 2-3 months, depending on extent of 
disease at presentation.^ One widely quoted study is that of the VA 
47 
Lung Study Group, in which 38 SCCL patients with limited disease 
achieved a median survival of 11.7 weeks and 108 patients with 
extensive disease achieved a median survival of 5.0 weeks on placebo. 
88 
In a cooperative VA study reported by Roswit et al., 
placebo-treated SCCL patients with limited disease had a median 
survival of more than 16 weeks. 
Surgery was one of the first modalities used to treat SCCL. The 
results were not good. Even apparently resectable lesions were 
frequently found to have seeded distant sites; relapse was the rule. 
A study of pathology material from the tumors of 19 patients who died 
within 30 days of apparently successful surgical resection found 
persistent disease in 13 of 19 patients, 12 of whom had distant 
89 
metastases. Radiation therapy (RT) alone proved better than surgery 
90 
in a British Medical Research Council trial. The patients had 

limited disease thought to be resectable and were fit enough for 
surgery or radical RT. At 10 year follow-up, the surgery group had a 
mean survival of 199 days, the RT group 300 days. Three patients in 
the RT group who survived five years remained alive and disease-free 
at 10 years. Four RT patients died between 2 and 5 years. The sole 5 
year survivor in the surgery group in fact underwent no surgical 
treatment due to breathlessness and received RT instead. 
88 
In contrast, in a cooperative VA study already mentioned, there 
was no significant increase in survival for a group with limited 
disease receiving 4-5,000 rads of RT compared to a placebo group. 
Median survival for the RT group was a bit over 16 weeks. 
74 
Selawry, in a 1973 report, reviewed the response of SCCL to 
single agent chemotherapy. Small cell was found to be the most 
responsive to single agents of all lung cancer subtypes. 
Therapeutic design moved quickly once the efficacy of 
chemotherapy had been shown. Radiation therapy was combined with 
91 
chemotherapy, creating a multi-modal approach; multiple 
87 92 
chemotherapeutic agents were employed. ’ It became clear that 
patients who achieved complete response lived longer than those 
achieving partial response or no response (in complete responders, the 
disease had been made clinically undetectable); and partial responders 
93 
seemed to live longer than non-responders. 
Chemotherapy has become the backbone of therapeutic approaches to 
SCCL. Basic principles of chemotherapy design have been applied to 
the disease. Attempts have been made to: combine drugs which have 

35 
therapeutic efficacy as single agents; choose combinations of drugs 
with different modes of action; treat with apparently non-cross- 
resistant sequential combinations of drugs; find combinations of drugs 
with synergistic anti-tumor effects; and use drug dosages high enough 
to maximize dose-response advantages while minimizing the inherent 
trade-off of dose-related toxicity. 
Disease extent is a major prognostic factor in SCCL and treatment 
results reflect this fact. It is wise to discuss therapy of limited 
disease and extensive disease separately. In general, limited disease 
treatment has changed little in the past five years and is dominated 
by controversies over the use of radiation therapy to the chest and 
prophylactic cranial irradiation as adjuvants to combination 
chemotherapy. An exception to this statement is the renewed interest 
in surgery as an adjuvant therapy in resectable lesions. The more 
creative approaches to therapy—new drugs, larger doses, 
non-cross-resistant sequential combinations—have been confined 
largely to treatment of extensive disease or patients who have 
relapsed. The reason for this is that current conservative 
therapeutic designs produce a predictable, although small, number of 
long-term survivors in the limited disease group; the extensive 
93 
disease group has fewer responders and shorter survival. Clinicians 
are reluctant to give up "acceptable" survival and known toxicity 
risks for experimental therapies. 
65 
Aisner et al., reporting for the International Association for 
the Study of Lung Cancer have summarized current expectations in 
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trials employing aggressive therapy against SCCL. Combination 
chemotherapy should produce complete response in more than 50% of 
patients with limited disease (LD) and more than 20% of patients with 
extensive disease (ED). With adequate staging, median survival of at 
least 14 months in LD and 7 months in ED may be expected. Finally, 
15-20% of LD patients should achieve disease-free survival of 3 years 
or more although such survivors remain rare among ED patients. 
Table 7 presents a summary of selected treatment protocols for 
SCCL. It is intended to show the evolution of therapy and variability 
of treatment results. It does not present highly experimental 
approaches of the kind usually reserved for extensive disease patients 
or patients who have relapsed from first-line therapy. Unless drawn 
from the same paper, the studies are not comparable. 
Table 8 presents information on long-term survivors from studies 
using various treatment modalities. 
Treatment of Limited-Stage Disease and 
Treatment-Related Toxicities 
Two controversial aspects of therapy design are especially 
relevant to limited disease, since their goal is prophylaxis or rapid, 
effective local control: the use of prophylactic cranial irradiation 
(PCI); and intrathoracic irradiation for local tumor control, both as 
adjuvants to combination chemotherapy. 
Neither non-randomized nor randomized trials of PCI have 
99,103 




Baglan and Marks thus argued that the nominal purpose of PCI 
was to prevent neurological signs and symptoms, since their review of 
the literature uncovered an incidence of brain metastases averaging 
23% for patients not receiving PCI versus 5% for the PCI group. The 
authors were able to treat 64% of 39 patients with brain metastases 
(all but 4 of whom were symptomatic) successfully enough to eradicate 
symptoms for the rest of the patients' lives. The authors predicted 
that, based on their results treating symptomatic patients and on 
previous treatment results with PCI, of 100 prophylactically 
irradiated and 100 symptomatically irradiated patients, 77 extra 
patients would have to receive PCI so that 3 patients might be spared 
CNS symptoms. They considered the potential benefit of PCI to be 
insignificant. 
Baglan and Marks's argument hinges on effective treatment of CNS 
metastases. Agreement on this point is not uniform;still, a 
recent NCI study indicated that brain metastases can be treated 
effectively enough so that such patients die of other causes in most 
102 
cases. 
A large retrospective NCI study^^ examined PCI with a special 
interest in: PCI timing; PCI's effect on long-term survival; and 
selection of any subgroups of patients for whom PCI would be most 
helpful. The results were of great interest: there was significant 
improvement in overall survival for the group receiving PCI. However, 
the group which received no PCI also had the least intensive 
chemotherapy. With that caveat in mind, the authors felt that PCI had 
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its greatest positive effect in the complete responders (with limited 
or extensive disease). Among patients achieving complete response who 
had received no PCI, 17% relapsed in a CNS site alone. Isolated CNS 
relapse was seen in no complete responders who had received PCI. Two 
and three year survival was improved in the PCI groups, but not 
significantly so. With respect to the timing of PCI: there were no 
CNS relapses in the first four months in any group and no striking 
treatment result differences between a group receiving PCI on day 1 of 
the protocol and a group receiving PCI at week 12 or 24, contingent on 
a complete or partial therapy response. 
The NCI group thus suggested that PCI may be most effectively 
employed at 2-4 months, after documented complete response has been 
achieved. Patients achieving less than complete response could be 
treated symptomatically since the study found no apparent advantage 
103 
using PCI in that group. A recent study from Toronto found no 
increased survival but significantly decreased brain relapse at 2 
years for complete responders receiving PCI (21% vs. 52%). 
Data is accumulating to support selective use of PCI—the data is 
on toxicities associated with PCI. Numerous groups have reported 
neurological toxicities among long-term survivors which may be due to 
PCI or the combination of PCI and chemotherapy (nitrosureas, in 
. x 84,104,105 . T j, . 106 , 
particular). A group at Indiana University found 
neurologic problems in 9 of 11 long-term disease free patients (>3 
years) who had received PCI + nitrosureas, and in 6 of 8 patients who 
had received PCI and chemotherapy without nitrosureas. Onset of 
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neurological symptoms was usually 1-3 years after completion of 
therapy. Problems encountered included memory loss, dementia, 
confusion, ataxia, psychomotor retardation, dysphonia and optic 
atrophy. Two patients required institutionalization; 6 others have 
had great impairment of their daily lives. Only 4 of 18 patients have 
had no neurologic impairment after therapy. Recently, a prospective 
evaluation revealed an '’extraordinary high frequency of CCT 
(computerized cranial tomography) abnormalities in patients with SCCL 
after treatment with chemotherapy and cranial irradiation...."^^ 
The role of PCI in the treatment of SCCL remains unclear. It 
appears that PCI may offer a relapse protection advantage in patients 
achieving a complete response that is worth the risk of possible 
long-term neurological side effects. Much may depend on the side 
effects clinicians are willing to tolerate to protect the subgroup of 
complete responders who, without PCI, would experience isolated CNS 
relapse. Neurological side effects need to be further studied so that 
especially toxic PCI-chemotherapy combinations can be avoided. More 
data are needed on survival, relapse, and toxicity through randomized 
trials of PCI in complete responders. 
The controversy surrounding the use of radiation therapy to the 
chest to complement multi-agent chemotherapy is a complex one. 
Multi-modal therapy, referring to combined radiation and 
chemotherapy, is of two main types: sequential and concurrent. In 
sequential therapy, there is a temporal pause between the two 




Catane et al., found a trend favoring concurrent therapy over 
sequential therapy for increased two year survival. The difference 
was not statistically significant, however. The concurrent therapy 
group achieved better complete therapy response with local tumor 
control and, of patients achieving complete response, fewer patients 
receiving concurrent therapy relapsed in the radiation therapy 
portal. 
The toxicity enhancement effects of concurrent therapy are 
critical in evaluation of protocol design. In Catane's study, 7 of 14 
patients receiving maximal concurrent radiation and chemotherapy (9 
weeks) died of treatment toxicity. Yet, 4 of the 7 treatment 
survivors achieved 2 year survival—the highest proportion of any 
group in the study. The authors concluded that 3 weeks of concurrent 
radiation therapy (RT) and chemotherapy (CT) produced the optimal 
combination of high 2 year survival and acceptable toxicity. 
109 
Cox et al., found that tumor control probability, assessed by 
serial chest radiographs, increased with increasing biological dose in 
patients treated with RT alone. But in RT + CT patients, local 
control was achieved at lower RT doses than would have been expected. 
RT was generally begun during the last week or immediately after 
completion of chemotherapy. 
The point is that RT and CT appear to act synergistically: they 
enhance each other's treatment effects but they also enhance 
toxicities. Acute toxicity enhancement effects include myocardial, 
pulmonary, skin and esophageal damage with Adriamycin; chronic 
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toxicities will be discussed shortly. However, delay of one week 
between modalities is thought to be protective. 
We enter the RT + CT vs. CT alone controversy with this 
perspective: the timing of combined modality treatment is important 
for toxicity and anti-tumor effects; RT seems to act synergistically 
with CT on tumor cells. To date, the critical parameters of RT-CT 
combination therapy—timing and dosage—have not been adequately 
, 111 
studied. 
The main argument for combined modality treatment is local tumor 
112 
control. Byhardt and Cox argue that failure of chemotherapy alone 
to prevent relapses in the chest is the reason to add adjuvant RT. 
Combined modality therapy reduces relapses in the radiation portal 
and, with this local tumor control, allows better long-term survival 
for limited disease patients. 
113 
Cohen notes that the true test of adjuvant RT is whether or 
not it increases the number of long-term survivors—i.e., patients 
living at least three years—in randomized trials comparing RT + CT to 
CT alone. 
The use of adjuvant RT in extensive disease is not as 
controversial a topic. Most investigators seem to agree that survival 
is not increased by RT to the primary tumor. The data supporting this 
114 
notion are relatively scanty, but meticulous local control 
apparently strikes most investigators as less essential when the tumor 
has already spread beyond one hemithorax. What can be said about 
local control and its relationship to long-term survival? 
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Peschel et in a retrospective review of 12 patients 
achieving survival of more than 2 years, stressed the need for local 
tumor control—surgery or high dose (>4800 rads) lung irradiation—to 
avoid local relapse. Three of 5 patients who had received 
chemotherapy alone or low dose irradiation (<3500 rads) had late local 
83 
relapses. Similarly, Matthews et al. reported on the treatment 
received by patients in their long term (>2.5 year) survival 
registry. The two largest groups represented were patients who had 
received RT + CT and those who had received surgery alone. (The role 
of adjuvant surgery in current treatment protocols will be discussed 
later.) 
Several controlled, randomized studies have compared CT + RT to 
116 
CT alone. Hansen et al. reported shorter median survival in the RT 
+ CT group compared to the CT group. In contrast, Bunn et al3^ and 
118 
Perez et al. reported better median survival and complete response 
rate with thoracic irradiation. The Perez study also reported an 
initial, significant superiority in actuarial 3 year survival for the 
group receiving RT (20% vs. 5%). Toxicity was greater in the RT + CT 
group. There were 2 induction deaths in the RT + CT group vs. none in 
119 
the CT group in Bunn's study. Mira et al. have added RT to CT at 
day 85 of their protocol and found that, in about 1/3 of responders 
who did not achieve complete response after initial CT, RT increased 
complete response rate and median survival. 
Radiation therapy to the chest has a logical place in the care of 
patients with limited-stage disease. Local control is an extremely 
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useful concept in designing treatment protocols for long-term 
survival. Still, the trade-off is increased toxicity. 
This is a good point to review treatment toxicities briefly, with 
a special interest in toxicities associated with combined modality 
120 121a 
therapy. ’ Most chemotherapy regimens used for treating SCCL 
produce some degree of myelosuppression. Addition of radiation 
affects the bone marrow and in a healthy adult, ribs, sternum, and 
121b 
scapula comprise 15-20% of functioning bone marrow. “ With most 
standard CT protocols the duration of granulocytopenia is relatively 
short; febrile episodes are reported in about 30% of patients, 
documented infections in 5%, fatal infections in 2%. When adjuvant RT 
is added, infections have been reported to rise to 11.7%, fatal 
120 
infections to 2.7%. Infection can be documented in about 40% of 
febrile, neutropenic patients; 50% of these have bacteremia. A total 
of 60% of febrile, neutropenic patients are thought to be infected on 
120 
the basis of cultures or clinical signs or symptoms. Thus, 
antimicrobial therapy is empirically employed in all such patients. 
Radiation therapy alone—but especially in combination with 
chemotherapy—contributes to two major acute toxicities: esophagitis 
and pneumonitis. 
As has been mentioned, Adriamycin enhances radiation induced 
esophagitis. Chronic esophageal stricture is a hazard avoided through 
careful planning of the portals and timing of RT and of the dose and 
type of cytotoxic therapy. 
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CT adds to the problem of radiation pneumonitis; also, chronic 
pulmonary fibrosis has emerged as a major concern in long-term 
survivors after multi-modal therapy 5^ 
Cardiac toxicity is a potential complication of SCCL treatment. 
Pericarditis, aggravation of coronary artery disease, and 
cardiomyopathies especially associated with Adriamycin are all 
potential toxicities. 
Peripheral neuropathy is a toxicity associated with vincristine. 
The long-term neurological sequelae of CT + RT have already been 
discussed in the context of prophylactic cranial irradiation. 
Finally, second malignancies are arising as toxic complications. 
Four cases of acute leukemia—all arising 2-1/2 to 3 years after 
120 
diagnosis of SCCL—have been reviewed by Abeloff et al. All four 
patients had achieved complete responses; 3 of the 4 had received 
multi-modal CT + RT therapy. 
Adjuvant surgery is a final topic to discuss in the treatment of 
limited-stage SCCL. Two studies have been mentioned which examined 
83 115 
the characteristics of long-term survivors with SCCL; ’ in each 
study, patients who had received surgery as initial or only treatment 
formed a significant subgroup. 
122 
The role of adjuvant surgery remains unclear. Comis et al. 
contributed a relatively early study, which they have recently 
123 
updated. TNM staging was used for the surgical procedure; the 
authors found that patients with superior mediastinal (N2) disease did 
124 
not seem to benefit from adjuvant surgery. Foster et al. found 
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that—due to extent of disease or such factors as poor medical 
condition and inadequate pulmonary function—only 10 of 37 eligible 
125 
limited disease patients were surgical candidates. Friess et al., 
in a retrospective review, found that the 15 patients with limited 
disease who had entered one of their combined modality protocols after 
surgical resection had significantly better median and 2 year survival 
than patients without initial surgery. The best median survival was 
in patients with the smallest lesions (<5 cm) who had undergone 
surgery before starting the protocol. 
Adjuvant surgery in SCCL may become an accepted treatment 
122 
modality. Comis et al. have some good initial results, but the 
number of patients is very small. Basic questions remain. When is 
adjuvant surgery most effective? (I.e., should it be employed before 
or after initial chemotherapy?) Is adjuvant surgery only possible or 
efficacious in a relatively small number of patients? Finally: are 
the results of adjuvant surgery going to reflect better treatment or 
simply the better prognosis of a subgroup of patients with "very 
limited" stage disease?^ 
Extensive-Stage Disease and Experimental Therapies 
114 
Comis, in his review of treatment for SCCL, considers 
infrequent long-term survival to be the distinguishing characteristic 
of extensive-stage disease. Intensive therapies (high dose, high 
toxicity; multiple, novel combinations; new drugs) have achieved 




survivors (>2.5 years) reported in 1980 reveals that, of 97 
patients, only 8 presented with extensive-stage disease. Extent of 
disease is a powerful prognostic indicator and survival data reflect 
this fact. 
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Comis cites the following as the most prevalent new approaches 
to extensive disease: increasing the intensity of chemotherapy; using 
a sequence of drug combinations which are thought to be 
non-cross-resistant; and incorporating Etoposide (VP-16-213) into the 
initial combination of drugs. 
Intensive chemotherapy seeks to take advantage of dose-response 
relationships and of the intuitive notion that if "effective" is good 
65 
"intensive" is better. Aisner et al. point to the paucity of data 
on dose schedule dependency. The determination of maximum doses 
proceeds slowly, on a drug-by-drug basis. Maximum acceptable toxicity 
appears to be the end-point. The results have not been encouraging 
and toxicity risks are considerable. Late intensive combined modality 
126 
therapy with autologous bone marrow infusion and high-dose therapy 
with protected environment-prophylactic antibiotic units to reduce 
127 
infectious morbidity have been reported to yield no long-term 
survival advantage over more conventional therapy. Neutropenia and 
infection are prominent risks. High dose regimens may be especially 
beneficial in patients achieving complete response;^however, the 
generally low rate of complete response among extensive disease 
patients limits their potential application. 
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Another novel approach to therapy is the use of 
non-cross-resistant drug combinations in cycles. The results have not 
114 129 
been exciting; ’ still, the approach may hold some promise. 
130 
Evans et al. have pointed out that most alternating sequences of 
drugs do not appear to be truly non-cross-resistant. They cite a 
truly non-cross resistant sequence study in which response was 
131 
improved. Still, "truly non-cross-resistant" seems to mean that 
potentially better response is achieved by achieving potentially 
better response—a suspiciously circular chain of reasoning. 
New drug development is, of course, a major focus of continuing 
research. These drugs, for ethical reasons, are usually tested 
initially in patients for whom first-line chemotherapy has failed. 
Aisner et al.^ note the hazards of this approach. It may be that 
aggressive initial therapy alters the nature of the tumor so that it 
becomes refractory to any subsequent treatment. (Evidence that 
therapy changes biochemical and histological characteristics of SCCL 
81 82 
tumors has already been noted in this paper. ’ ) Aisner cites 
Etoposide and vindesine as examples. Etoposide is probably the most 
active single agent in untreated SCCL, with response rates averaging 
130 
over 40%. Yet, the drug has generally been found to produce 
insignificant response rates in patients refractory to standard 
130 
therapy. Perhaps the problem is not pre-treatment, but simply that 
tumors unresponsive to first-line therapy are refractory to most novel 
therapies as well. 
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In any case, Etoposide (VP-16-213) has proved to be a promising 
new agent in treating SCCL. It appears to show a dose-response 
relationship; a study of high-dose Etoposide achieved an 80% response 
132 
rate in 10 patients with extensive disease. Etoposide is often 
used in current multi-agent chemotherapy combinations. 
133 13A 133 
VM-26 (related to vincristine), vindesine, ’ and, 
136 
"logically,M vindesine + Etoposide may have activity against 
SCCL. The latter seems a good example of combining two drugs to see 
if the combination proves to have some magical synergism. Sometimes 
synergism is found. When Etoposide alone was compared to Etoposide + 
cis-platin (EP) in patients refractory to cyclophosphamide- 
130 
Adriamycin—vincristine (CAV) therapy , the EP group experienced a 
better response rate, higher median survival and increased 
thrombocytopenia all thought to reflect the synergistic action of 
Etoposide and cis-platin described in some animal tumor 
137 
systems. Since their patients had been refractory to CAV therapy, 
the authors suggested they may have found a truly non-cross-resistant 
sequence for further investigation (CAV-EP). The usefulness of EP as 
consolidation therapy after initial CAV or "combined alkylators" has 
been reported to show little promise. 
Finally, mention should be made of two studies similar to the 
Yale treatment protocol for SCCL whose results appear in the next 
139 
section of this paper. Zekan et al. found that CAVE afforded 
significantly increased total treatment response over CAV (82% 
vs. 66%). Etoposide was said to have added little toxicity although 
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3/57 CAVE patients suffered treatment-related deaths vs. 1/59 CAV 
patients. Estimated median survival was not significantly different 
for the two treatment groups in limited disease or extensive disease. 
140 
Messeih et al. reported a significantly increased overall 
response rate (65% vs. 50%), and complete response rate (44% vs. 18%) 
for their CAVE group and—strikingly—extensive disease patients 
achieved a complete response rate of 35% on CAVE versus 0% on CAV. 
Overall median survival for all responders and median survival for 
complete responders was not significantly different for the two 
treatment groups. 
Closing Comments 
Despite the tantalizing response of SCCL to initial radiation or 
chemotherapy, relapse is the rule. Long-term survival (best defined 
as longer than 4-5 years if any association with cure is to be 
implied) is rare. Extensive disease patients have an especially 
dismal prognosis but this may improve if more can achieve complete 
response to therapy. Still, the disease remains one in which many 
patients are treated to allow survival of a few. Severe treatment 
toxicities can be avoided with rational dosage, timing, and selection 
of therapeutic modalities. They should be avoided, for there is no 
evidence that toxic therapies are the best therapies, and when cure is 
rare treatment should be relatively palatable. 
Limited-stage disease offers the most hope. Prophylactic cranial 
irradiation (PCI) appears to have enough chronic neurological 
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toxicities that its use is best limited to complete responders, two to 
four months after the start of therapy. Thus, PCI will be employed 
mostly in limited-stage disease. PCI may fall out of favor entirely 
if, for example, its chronic toxicities are found to outweigh its 
protection of the subgroup of patients who would otherwise suffer 
isolated CNS relapse. Nitrosureas appear to be especially associated 
with the chronic toxicity of PCI. Patients with less than complete 
responses can be treated for CNS metastases as they arise. Chest 
irradiation makes a great deal of sense in limited disease; there is 
enough clinical evidence and good theoretical speculation to support 
the notion that local control of intrathoracic disease is essential 
for long-term survival. Care must be taken to avoid acute toxicities 
that accompany multi-modal therapy; chronic pulmonary toxicity is a 
significant factor which requires further study. 
The importance of local control makes adjuvant surgery a 
potentially useful treatment modality. The apparently superior 
survival of patients with small "very limited" tumors highlights the 
need for a biochemical marker or other method of early diagnosis 
before SCCL becomes clinically apparent. If high risk populations 
could be screened for the disease, survival in SCCL would certainly 
improve, even with the limitations of current therapy. 
Our understanding of SCCL is poor. The variability of treatment 
results and the resistance of small cell tumors to second-line drugs 
are but two reflections of our ignorance in the clinical setting. The 
variability among pathologists in identifying tumor subtypes and the 
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lack of apparent prognostic significance of these subtypes make the 
current system of histological classification questionable. 
Heterogeneity is the hallmark of SCCL: tumor cells are variable 
in chromosome number, proliferative activity, antigenic expression, 
clonal origin, cytomorphology and biochemical behavior (including 
expression of tumor products and biochemical markers). Tumor cells 
with few or no neurosecretory granules, low dopa decarboxylase and 
bombesin activity, high ploidy and active proliferative behavior have 
all been identified as belonging to a clinically more aggressive 
subclasss. The "variant" subclass of tumor cells may be both 
radioresistant and more aggressive than the "classic" subclass. The 
origin of aggressive tumor cells is obscure since dopa decarboxylase 
and neurosecretory granules are distinguishing APUD characteristics. 
Perhaps they evolve from cells in the original tumor (i.e., the tumor 
formed by initial malignant transformation). 
The reclassification of SCCL proposed by the pathology panel of 
the International Association for the Study of Lung Cancer is of great 
significance. It is thought that the NCI's "variant" subclass tumor 
cells are the _in_ vitro equivalent of the proposed small cell-large 
cell subgroup, and that the NCI's "classic" cells are the in vitro 
equivalent of the proposed classic small cell subgroup. If, for the 
first time, a prognostically significant classification system has 
been found, whose subtypes can be reliably identified by different 
pathologists and studied with equivalent in vitro cell lines, then a 
major step will have been taken in the struggle to link basic science 
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research on cellular characteristics with clinical practice. Until 
then, information on the heterogeneity of SCCL tumor cells and the 
cellular characteristics of clinically aggressive tumors goes beyond 
our ability to use it: the information doesn't help in diagnosis, for 
our diagnostic tools detect only gross disease; it doesn't clarify our 
histological classification system, which is based on light 
microscopy; it doesn't assist us in prognosis, which is based on gross 
extent of disease and subjective evaluation of a patient's ability to 
carry out his daily tasks; and it probably won't help us design better 
therapy, since our therapeutic modalities are so very limited. But 
only work on cells will characterize the SCCL tumor. Our methods of 
diagnosis, classification, prognosis, and treatment will become more 
refined as understanding of the tumor cells expands. New 
modalities—hyperthermia, monoclonal antibodies, radiosensitizing 
drugs^—may prove useful by empirical trial. Today's dilemma is that 
a hit-or-miss approach to SCCL is bound to fail and the information we 
need for rational therapy is elusively basic. 
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PART THREE: THE STUDY 
This paper presents the initial results of a Yale University 
treatment protocol for small cell cancer of the lung (SCCL). The data 
are part of a continuing study; methods, patients, results, and 
discussion are presented below. 
Methods 
During the period October, 1980 to April, 1983 all referred 
patients with histologically confirmed SCCL (by cytology or biopsy of 
metastatic sites) were entered in the study. Patients were accepted 
regardless of stage of disease, performance status, or life 
expectancy, provided they had at least one site of measureable or 
evaluable disease. Patients were ineligible for inclusion in the 
study if they had received prior treatment for their disease, with the 
exception of surgery, or if their left ventricular ejection fraction, 
by gated blood pool scan, was too low to permit treatment with 
Adriamycin (doxorubicin). 
Pretreatment staging evaluation included history and physical 
examination with evaluation of performance status. Blood tests 
included CBC, platelet count, BUN, creatinine, bilirubin 
(total/direct), alkaline phosphatase, glucose, electrolytes, 
prothrombin time/partial thromboplastin time, cortisol, and studies 
for ectopic hormones as indicated. 
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Diagnostic procedures included bone marrow biopsy and aspirate; 
chest x-ray with tomography in all patients with limited-stage disease 
and others as indicated; liver-spleen scan and bone radionuclide 
scans; CT scan of the head; skin tests for SKSD, PPD, Candida, mumps; 
electrocardiogram; and left ventricular ejection fraction gated blood 
pool scan. 
Patients were defined as having limited-stage disease (LD) if the 
disease was confined to one hemithorax, with or without involvement of 
hilar, mediastinal and ipsilateral supraclavicular lymph nodes. 
Extensive-stage disease (ED) was defined as disease beyond these 
confines. 
For treatment, patients were randomized prospectively to CAV 
(cyclophosphamide, Adriamycin, vincristine) or CAV/E (the above plus 
2 
Etoposide (VP-16-213). Drug dosages were: Adriamycin 40 mg/m"; 
2 2 
cyclophosphamide 1000 mg/m IV; vincristine 1.4 mg/m" IV (not to 
2 
exceed a total dose of 2 mg); Etoposide 125 mg/m" IV. CAV cycles were 
every 21 days. CAV/E cycles were every 42 days, with CAV given on day 
2 
1, Etoposide 125 mg/m" IV on each of days 21, 23, and 25, beginning 
again with CAV on day 42. 
In limited disease, 3000 rads of radiation therapy (RT) to the 
primary tumor, mediastinum, and bilateral supraclavicular nodes as 300 
rads per day, 5 treatments per week (10 treatments total) was given 
initially. Vincristine and cyclophosphamide in the doses above were 
given after staging, concurrent with the first phase of RT, followed 
by 4 cycles of CAV or 2 cycles of CAV/E. Adriamycin-containing 
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combination therapy thus began after completion of the first phase of 
RT and at least 21 days after initial cyclophosphamide and 
vincristine. An additional 2400 rads of RT to the primary sites, with 
concurrent cyclophosphamide and vincristine, were given as 8 
treatments of 300 rads each, after the first 4 cycles of CAV or 2 
cycles of CAV/E, before completing 6 more cycles of CAV or 3 more 
cycles of CAV/E. 
In extensive disease, treatment was as above, except irradiation 
of the primary site was at the option of the responsible clinician. 
After cycle 4 of CAV or cycle 2 of CAV/E, all complete responders 
with no known brain metastases received prophylactic whole brain 
irradiation as 3000 rads over 2 weeks at 300 rads per treatment, 
regardless of disease extent at presentation. 
Treatment was continued to 10 cycles of CAV or 5 cycles of CAV/E. 
See Tables 9 and 10 for summaries of the treatment protocols. 
If, after 6-8 weeks of chemotherapy, there was disease 
progression, patients were considered off-study and treatment was 
individualized. Otherwise, patients were treated per protocol until 
clear-cut evidence of progression or relapse. Subsequent therapy was 
individualized. 
At the conclusion of therapy, patients were restaged to document 
response. 
Dose attenuations were guided by CBC prior to therapy. 
Complete response was defined as total disappearance of all 
disease with biopsy confirmation (e.g., for bone marrow or liver) 
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lasting at least 30 days. 
Partial response was defined as a 50% decrease in the product of 
2 tumor diameters perpendicular to one another, without associated 
progression of any other lesions or the appearance of a new lesion. 
Regression had to last a minimum of 60 days. 
Stable disease was defined as less than 50% regression of 
measureable lesions with the appearance of no new lesions and no 
deterioration of performance status. 
Progression of disease was defined as the appearance of any new 
lesion or the increase in size of any measureable lesion by greater 
than 50%. 
In this report, patients with stable disease and progressive 
disease are grouped together as "non-responders." 
EC0G toxicity criteria were used as a basis for patient 
comparison. 
Performance status was defined as follows: 0-asymptomatic; 
1-fully ambulatory with symptoms; 2-bedridden less than 50% of the 
time; 3-bedridden 50% of the time or more; 4-100% bedridden. 
Statistical analysis of time to relapse and survival was 
performed using Kaplan-Meier plots; comparisons were made using the 
generalized Wilcoxon (Breslow) test of statistics. All median values 
are from the Kaplan-Meier plots and therefore may be projections. 
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Patients and Results 
Of the 47 patients entered into the study, 8 were inevaluable. 
Five of the 8 patients had extensive disease (ED). Of these 5: 2 
patients never got Adriamycin due to inadequate pre-treatment cardiac 
function; 1 had intercurrent prostatic cancer; 1 chose to leave the 
care of a physician participating in the study after one visit, for 
unknown reasons; and 1 patient had a sudden cardiac death 48 hours 
after her only cycle of CAV therapy. 
Three of the 8 inevaluable patients had limited disease (LD). 
Of these 3: 1 patient had not been on-study long enough to evaluate 
response—in addition, this patient's tumor was of mixed small 
cell/large cell histology; 1 had intercurrent prostate cancer; and 1 
patient's chemotherapy was discontinued at the patient's request when 
symptoms of congestive heart failure developed after one dose each of 
cyclophosphamide and vincristine (the cycle contained no Adriamycin). 
On-study time was defined as the date treatment started to the 
date last seen or date of death. The 39 evaluable patients had a 
median on-study time of 219 days (range 6-907 days). 
Twenty-eight of 39 patients have relapsed. Eleven of 39 patients 
have not relapsed, one of whom died without apparent relapse (of 
infection or radiation pneumonitis, as will be described later); the 
other ten patients are still living and are disease-free. Sixteen of 
39 patients are still alive, including 6 who have relapsed. The 
median follow-up for patients still alive is 219 days (two shortest 
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follow-ups: 70 and 97 days; two longest: 674 and 907 days). 
Patient characteristics are presented in Table 11, subdivided by 
extent of disease and treatment arm. Fifteen of 39 patients (38%) had 
limited disease (LD). Twenty-four of 39 (62%) had extensive disease 
(ED). Two ED patients presented with superior vena cava syndrome; 1 ED 
patient had SIADH on presentation. One LD patient had significant 
non-neoplastic disease on presentation (diffuse scleroderma; she is 
the only patient whose initial performance status is unknown). 
As expected, LD patients had better initial performance status 
than ED patients (LD—11 of 15 patients fully ambulatory (performance 
status 0 or 1); ED—11 of 24 patients fully ambulatory). The LD group 
was slightly younger than the ED group (median ages: LD-60 years; 
ED-63.5 years). The LD group contained a greater proportion of women 
(LD- 9 women:6 men; ED- 11 women:13 men). 
Comparing treatment arm groups (Table 11): On the whole, the CAV 
group contained younger patients (median ages: CAV-59 years; CAV/E-66 
years). LD-ED distribution was similar for both treatment groups: of 
21 CAV patients, there were 8 LD (38%) and 13 ED (62%); of 18 CAV/E 
patients, there were 7 LD (39%), 11 ED (61%). 
Fourteen of 21 CAV patients (67%) were fully ambulatory 
(performance status 0 or 1) versus 8 of 18 CAV/E patients (44%). Most 
of this difference can be accounted for by the fact that 8 of 13 
patients (62%) in the ED-CAV group were fully ambulatory versus 3 of 
11 patients (27%) in the ED-CAV/E group. 
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The CAV/E group contained a greater proportion of women (CAV/E- 
10 women:8 men; CAV- 10 women:11 men). 
Three patients had surgery before beginning the protocol: 2 LD, 
1 ED. Patient characteristics are continued in Tables 12 and 13. 
Eighteen of 24 ED patients presented with metastatic disease in 
more than one site. Sites of presenting metastases, by treatment arm, 
with the number and percentage of patients presenting with them are 
shown in Table 12. Six of 24 ED patients presented with metastatic 
disease involving single sites (see Table 12). 
Sites of relapse among all 39 patients (ED + LD) with the number 
and percentage of patients relapsing at those sites are presented in 
Table 13. There were 10 relapses in sites of initial disease, 
excluding the chest (see Table 13). 
Of the 5 brain relapses, 4 occurred in ED patients who had 
received no prophylactic cranial irradiation (PCI). Three of these 4 
patients received no CT scan or radionuclide brain scan on diagnosis. 
One of the 5 brain relapses occurred in an LD patient with negative CT 
scan on diagnosis who relapsed 4 months after 3000 rads of PCI. The 
ED patient who experienced a choroidal relapse had no PCI. 
Two LD patients deserve special mention. The first patient had a 
palpable subcutaneous nodule at diagnosis, refused biopsy, and later 
relapsed in the same site; the second had a radionuclide scan 
equivocal for liver involvement at diagnosis and later relapsed in 
liver, bone and bone marrow. 
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Nine patients had chest relapses. Five of the 9 had ED and 
received no thoracic irradiation. It is not known whether the 
remaining 4 patients (2 LD; 2 ED) relapsed within their radiation 
therapy portals. 
Response to therapy, grouped by disease extent and treatment arm, 
is presented in Table 14. Objective responses (CR + PR) occurred in 28 
of all 39 patients (72%); in 13 of 15 LD patients (87%); 15 of 24 ED 
patients (63%); 8 of 8 LD-CAV patients (100%); 5 of 7 LD-CAV/E 
patients (71%); 9 of 13 ED-CAV patients (69%); and 6 of 11 ED-CAV/E 
patients (55%). 
The following sections present data from Kaplan-Meier curves for 
time to relapse and survival. Subgrouping was performed in analyzing 
the data by treatment group (e.g., LD-CAV responders vs. LD-CAV/E 
responders); such subgrouping is intended only to reflect the 
distribution of the data, since the small number of patients in these 
subgroups precludes in-depth analysis. 
Time to relapse was defined as the date treatment began to the 
date of disease progression. The data are presented in Table 14 and 
Figures 1-4. 
Median time to relapse was 361 days in responders (CR + PR) with 
LD; for ED responders, the median was 188 days. Analysis of these 
relapse curves showed a significantly longer time to relapse for the 
LD responders (_p=.0001). (See Figure 1.) Time to relapse for ED 
non-responders (median: 71 days) was significantly shorter than for 
ED responders (2,= .006). (See Figure 2.) 

61 
Time to relapse was studied by treatment group. For patients 
with LD, time to relapse on CAV (median: 334 days) versus time to 
relapse on CAV/E (median: 361 days) was not significant 
(£=•55). (See Figure 3.) In contrast, time to relapse for all ED 
patients on CAV (median: 193 days) compared to ED patients on CAV/E 
(median: 109 days) was barely significant (£=.04). (See Figure 
4. ) Further subgrouping revealed that time to relapse of ED 
responders (CR + PR) on CAV versus those on CAV/E was not significant 
(_gj=. 77); but comparison of ED non-responders on CAV versus ED 
non-responders on CAV/E was significant (£=.02). 
Survival data, the main criteria by which protocols are 
evaluated, are presented in Table 15 and Figures 5-9. 
Median survival for all patients was 301 days. (See Figure 
5. ) Median survival for LD complete responders was 560 days. 
Survival of LD responders (CR + PR) (median: 560 days) was 
compared to survival of ED responders (median: 230 days) and found to 
be significant (£=.0007). (See Figure 6.) Survival of ED responders 
versus ED non-responders (median: 198 days) was not significant 
(£=.24). (See Figure 7.) 
Survival by treatment group was analyzed. When survival of LD 
patients on CAV (median: 560 days) was compared to LD patients on 
CAV/E (median: 424 days), no significant difference was found 
(£=.24). (See Figure 8.) Survival of ED patients on CAV 
(median: 230 days) versus ED patients on CAV/E (median: 186 days) 
was not significant (£=.23). (See Figure 9.) 
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A glance at the survival curve for all patients shows a plateau 
at about 6%. (See Figure 5.) The curve for LD complete responders 
plateaus at 35%. But 8 of the 12 patients in this group were still 
alive and those 8 had a median follow-up of only 305 days, while 
projected median survival was 560 days. 
Thusfar, 4 patients have lived 1-1/2 years or more. Two are 
described in some detail below because they will be mentioned in the 
discussion of treatment results later on. 
First, a male patient presented at 51 years of age with 
performance status 1 and extensive disease—bone involvement, pleural 
effusion of unknown cytology, a subcutaneous nodule in the left flank 
and a supra-clavicular node. After 4 cycles of therapy, his chest 
disease had not changed significantly; however, he experienced a 
choroidal relapse in the left eye, with detachment and uplifting of 
the retina. The patient received radiation therapy to the eye and 
additional cycles of CAV. His chest x-ray showed no significant 
improvement during 7 months of therapy—thus, he was a non-responder. 
However, he did not expire until 847 days after the start of therapy. 
Second, a 60-year-old woman with limited disease and performance 
status 0 underwent a left lower lobectomy then received CAV therapy, 
achieving complete response. She was still alive at 907 days, without 
relapse. 
Some toxicities were common but not severe enough to cause great 
concern: radiation esophagitis (never causing strictures or requiring 
hospitalization); nausea and vomiting (controllable); mucositis (never 
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precluding oral food consumption); alopecia. All were ECOG #2 
(moderate toxicity) or better. 
Myelosuppression significant enough to cause a drop in WBC count 
to <2000 (ECOG #3 or worse) was experienced by 24 of 39 patients 
(62%); 14 of 24 patients with ED (58%) and 10 of 15 with LD (67%); by 
treatment group: 16 of 21 CAV patients (76%); 8 of 18 CAV/E patients 
(44%). 
Anemia severe enough to require transfusion (ECOG #3) was 
experienced by 9 of 39 patients overall (23%); 5 of 24 with ED (21%); 
4 of 15 with LD (27%); 6 of 21 on CAV (29%); 3 of 18 on CAV/E 
(17%). Three patients require special mention; one extensive disease 
patient on CAV had a Hgb/Hct of 8.6/25.3 but no transfusion 
documented; one LD-CAV/E patient had Hgb/Hct of 10.1/25.5 but refused 
transfusion; one ED-CAV patient had chronic anemia status post Bilroth 
II surgery and his anemia was not evaluable as a toxicity. 
No platelet counts <50,000 (ECOG #3 or worse) were documented and 
there were no episodes of bleeding. 
Six patients were hospitalized 8 times for pneumonia; 3 episodes 
of concurrent sepsis were documented. Two patients were hospitalized 
three times for fever: one of these patients was hospitalized 
separately for pneumonia, and is included among such patients above; 
one patient was hospitalized twice with negative cultures but a left 
upper lobe cavitary lesion on chest x-ray and a positive PPD test. 
The latter patient was treated with INH and Rifampin. 
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One patient was hospitalized once with a lung abcess and failure 
to thrive. 
One patient was hospitalized once for pancytopenia (WBC count of 
300) but neither fever nor infection was documented. 
Eight patients were thus considered to have been hospitalized at 
some time for infection (all those described above except the patient 
with pancytopenia only). Seven of these 8 patients had ED; the one LD 
patient was hospitalized twice, once for pneumonia without sepsis, 
once for fever only. 
Thus, 7 of 24 ED patients (29%) experienced significant infection 
as did 1 of 15 LD patients (7%); 7 of 21 CAV patients (33%); and 1 of 
18 CAV/E patients (6%). One patient not included above may have died 
of treatment-related infection, as discussed below. 
Two patients, both with LD on CAV/E, experienced radiation 
pneumonitis, one requiring treatment with steroids. A third patient, 
with ED on CAV, who had superior vena cava syndrome and liver 
involvement at presentation, was hospitalized 12 days after her last 
chemotherapy cycle, 5 weeks after radiation therapy to the chest, with 
leukopenia, fever, chills, and bilateral pulmonary infiltrates. 
Cultures were negative, but she was begun on antibiotics. Her lung 
disease was thought to be consistent with radiation pneumonitis, but 
this was diagnosed by chest x-ray and clinical impression only. The 
patient progressed to "Adult Respiratory Distress Syndrome" after one 
week of hospitalization and expired two and one-half weeks after 
admission. This patient almost certainly died of treatment-related 
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toxicity. Infection is thought to be the most likely cause; radiation 
pneumonitis is a possibility. The patient died without documented 
relapse after a partial response to therapy. 
One inevaluable patient had a possible treatment-related death. 
She was a 70-year-old woman who presented with performance status 4, 
SIADH and extensive disease. Her cardiac ejection fraction was 
50%. She received one cycle of CAV therapy and had a sudden cardiac 
death 48 hours later. 
Three other patient deaths should be described. 
A patient with LD on CAV therapy who received prophylactic 
cranial irradiation (PCI) developed dementia, dizziness, and double 
vision. Her CNS symptoms progressed, and, in light of a lumbar 
puncture and CT scan negative for tumor, she was felt to have died of 
paraneoplastic encephalopathy. However, combined Adriamycin-radiation 
therapy toxicity cannot be ruled out. 
One patient with ED, a non-responder to CAV therapy, experienced 
dementia with memory loss and confusion. The patient’s CNS symptoms 
progressed and, in light of a CT scan and lumbar puncture negative for 
tumor, his death was felt to be consistent with paraneoplastic 
encephalopathy. The patient received no PCI. However, death due to 
toxicity of chemotherapy alone cannot be ruled out. 
Finally, a 58-year-old man presented with significant liver 
involvement, bilateral lymphadenopathy, and performance status of 
3. He was randomized to CAV/E therapy and died due to progression of 
his disease in the liver 6 days after his only therapy cycle, which 
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consisted of CAV. This patient is mentioned because his case will be 
noted in the discussion of treatment results later in the paper. 
Three patients experienced significant cutaneous infections. Two 
patients—one LD on CAV/E, one ED on CAV—experienced H. simplex 
infections while being hospitalized for concurrent problems. An ED 
patient on CAV/E experienced an H. Zoster infection as an outpatient. 
Three patients had rash reactions to chemotherapy: one to 
Adriamycin; one to Adriamycin and cyclophosphamide or cyclophosphamide 
alone; one unknown. Two patients required treatment with IV 
steroids. 
Adriamycin had to be discontinued in 2 patients due to 
cardiotoxicity. None experienced heart failure (both toxicities ECOG 
#2). One inevaluable patient experienced heart failure after a single 
cycle of chemotherapy which did not contain Adriamycin. Chemotherapy 
was discontinued at the patient's request. 
Vincristine neurotoxicity was significant enough to cause 
discontinuation of the drug in 4 patients (3 LD on CAV; 1 ED on 
CAV/E). One of these patients (ED) experienced "Etoposide accentuated 
vincristine neuropathy with foot drop" and both drugs were 
discontinued. The only other documented attenuation of Etoposide was 
one cycle of 3 doses for myelosuppression just before the patient 
relapsed. Vincristine dose attenuation of more than 50% was required 
in 4 patients (2 ED-CAV; 1 ED-CAV/E; 1 LD-CAV) for whom 
discontinuation of the drug was not necessary. 
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Finally, 7 patients required significant attenuations (>50%) in 
the dose of their chemotherapy (cyclophosphamide and/or Adriamycin) 
for myelosuppression alone: 3 ED-CAV; 1 ED-CAV/E; 2 LD-CAV/E; 1 
LD-CAV. 
Discussion 
The International Association for the Study of Lung Cancer 
Workshop has published its treatment result expectations for 
SCCL.^ Expectations include complete response of 50% in LD and 20% 
in ED; median survival of at least 14 months in LD and 7 months in ED; 
and 15-20% 3 year disease-free survival among LD patients. These 
expectations may be excessively optimistic (especially those for 
long-term survival—see Table 8), but at least they establish some 
standard for comparison. Table 7 presents treatment results from 
selected studies; direct comparisons are not possible between 
studies. 
The response rates in the present series were generally good, 
with 80% of LD patients achieving complete response. Just 12% of ED 
patients achieved complete response, a low but acceptable number. 
Projected median survival was very good, ranging from about 6.5 
months for ED non-responders to more than 18 months for LD complete 
responders. As expected, both time to relapse and survival were 
significantly longer for LD responders (CR + PR) than for ED 
responders. The presence in the ED non-responder group of a patient 
who survived 847 days after a choroidal relapse must be kept in mind 
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when evaluating the projected survival data for this relatively small 
group (n=9). The unusual choroidal relapse appears to have had no 
significant negative influence on this patient's survival. The 
projected median survival of 560 days for LD complete responders must 
also be approached with some caution since the projection is based on 
data from 12 patients, 8 of whom were still living. The living 
patients had a median follow-up of just 305 days. 
Of the 12 LD patients achieving complete response, one was alive 
and disease-free at 907 days (slightly less than 2.5 years). 
Interestingly, this patient had surgery prior to beginning the 
protocol, adding further anecdotal evidence to the efficacy of 
adjuvant surgery in achieving local control and the importance of 
local control in long-term survival. In fact, it is too soon to 
predict the number of long-term survivors from this study. 
The two treatment groups were very similar in survival results. 
The CAV/E group had shorter projected median survival in both ED and 
LD, but no comparison with CAV survival curves was significant. Time 
to relapse was shorter for the ED-CAV/E group than the ED-CAV group 
and the comparison was barely significant (j)=.Q4). Further 
subgrouping showed a significantly shorter time to relapse for the ED 
non-responders on CAV/E than those on CAV. Comparison of time to 
relapse for ED responders was not significantly different for the two 
treatment groups. There are numerous reasons for quicker time to 
relapse in ED non-responders on CAV/E. These include the fact that 
the ED-CAV/E group contained a substantially smaller proportion of 
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fully ambulatory patients than the ED-CAV group (62% vs. 27%). The ED 
non-responder CAV group contained that patient with the choroidal 
relapse who went on to relatively long survival while the ED-CAV/E 
non-responder group contained the patient who died of progressive 
disease in only 6 days. ED non-responders on CAV survived longer than 
ED non-responders on CAV/E but the groups are small and comparison 
didn't quite reach significance (_p_=.053). Interestingly, survival was 
better for the ED responders on CAV/E than those on CAV, but the 
comparison was not significant (j>=.41). 
Clearly, the addition of Etoposide to CAV produced no difference 
139,140 
m treatment results worthy of mention. lwo previous reports 
cited better response rates with the addition of Etoposide to CAV; 
still, the studies found no significant differences between the 
treatment groups in survival. 
No unexpected toxicities arose in the study. Myelosuppression 
was no greater than that consonant with a good therapeutic response. 
Etoposide added no apparent additional toxicity to the CAV 
regimen. In fact, only 1 of the 18 CAV/E patients (6%) required 
hospitalization for infection versus 7 of the 21 CAV patients 
(33%). The 33% rate for CAV patients is higher than the 11.7% 
"standard" infection rate for combined modality protocols cited in one 
120 
review of SCCL treatment complications. The 6% rate with CAV/E is 
lower than the "standard" rate and unexpected. Leukopenia (WBC count 
<2000) was experienced by 16 of 21 CAV patients (76%) versus 8 of 18 
CAV/E patients (44%). Perhaps this underlies the difference in 
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infection rates, unless Etoposide has some heretofore undiscovered 
antibiotic properties. 
One treatment-related death was probably caused by infection 
(although radiation pneumonitis is possible), yielding a fatal 
infection rate of 1 in 39 patients (2.6%). This is reasonable for a 
120 
combined modality study. Sudden cardiac death occurred after a 
single cycle of cyclophosphamide and vincristine in a patient 
presenting with extensive disease, SIADH, poor performance status 
(bedridden) and a cardiac ejection fraction of 50%. This must be 
viewed as a possible treatment-related death although no Adriamycin 
was given. 
In summary, the present study employed state-of-the-art design 
(prophylactic cranial irradiation after complete response, thoracic 
irradiation in limited disease, and use of Etoposide, an agent with 
significant activity against SCCL) and achieved early treatment 
results comparable to those in the current literature. It is too 
early to evaluate long-term survival. 
Addition of Etoposide to CAV therapy yielded no improvement in 
initial treatment results, including survival. However, an 
unexpectedly low rate of infections requiring hospitalization was 
found in the CAV/E group, substantially lower than that in the CAV 
141 
group, perhaps secondary to a lower rate of leukopenia with the use 
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14.5% 19.2% 23.9% 
Total subjects = 163 
From: Auerbach, 0., Garfinkel, L., and Parks, V.R. 
[14; 
Table J_ — Age Standardized Percentage Distribution of 






Exposure Group+ Excess Cases 
1 - 359 8.27* 
360 - 1779 22.07* 
> 1800 33.69* 
Combined groups 64.03* 
* = significantly different from expected number of cases (£.<.01) 
+Exposure is quantified by "Working Level Month" (WLM) Groups. One 
WLM is a month's work performed in an atmosphere containing a standard 
radiation dose per liter of air. 
From: Archer, J.E., Saccomano, G., and Jones, J.H. 
[16] 
Table 2. — Distribution of Excess (Presumably Radiation-Induced) 




Percentage of patients with the symptom 
Cohen and Matthews 
[12] 
Friesenhahn, et al. 
[44] 
Cough 76 37 
Chest pain 36 28 
Dyspnea 34 31 
Pneumonitis 25 NR 
Wheeze 22 NR 
Hemoptysis 15 17 
Fatigue NR 21 
Hoarseness 15 NR 
SVC syndrome 12 NR 
NR = Not Reported 
Table 3. — Symptoms of SCCL 

88 
At Presentation^"^ At Autopsy^^ 
(total pts = 375) (total pts = 163) 
Liver 32 61.7 
Bone 30 35 
Bone marrow 16 NR 
Brain 14 50 
Skin, soft tissue, 
nodes 
16 75.5 (excluding 
"chest wall") 
Effusion/pleura 15 22.7 
Heart NR 20.3 
NR = Not Reported 
r 45 l 
From: Livingston, R.B., Trauth, C.J., Greenstr^et, R.L. J and 
Auerbach, 0., Garfinkel, L., Parks, V. J 
Table 4. — Percent Distribution of Metastases at Presentation and 








































Osterlind K., Ihde, D.C. et al 
[57] 
Table _5 — Recommendations for Restaging 

Definite Stage of disease 
Performance status 
Probable Liver or CNS metastases 
Laboratory parameters 
Possible Weight loss 
Number of metastatic sites 
Age 
Sex 
Size of lesion ("very limited" vs. other) 
None Histologic subtype (1977 WHO classification) 
Investigational Histologic subtype (small cell-large cell vs 
classic small cell)+ 
Adapted from Ihde D.C., and Hansen, H.H.[48] 
+Proposed by pathology panel of the International Association for the 
Study of Lung Cancer.[73b] 
Table 6_ — Prognostic Factors in SCCL 

91 
Number Complete Median Survival 
of Pts Response (weeks) 
Treatment LD ED LD ED LD ED 
Placebo^4^ ^ 38 108 + + 11.7 5.0 
Placebo^88^ 29 + + + >16 + 
Surgery[90] 68 + + + 28.5a + 
Radiation^" ^ 70 + + 44a + 
p a ■ [88] Radiation 53 + + >16 + 
CAV + RT^94^ 108 250 41% 14% 52 26 
CME + RT^95J (38 LD + ED) 86% 27% 56 20 
CAVE + RTt96^ 33 11 76% 34% 92 36 
CAVE + RT^- 97 ^ 28 29 61% 21% 60 37 
MEV/ CAV / ^98 ^ 
MEV - CAV + 453 + 16% + 31 
+ = Inapplicable C = cyclophos phamide M = methotrexate 
'x' = Not Reported A = Adriamycin RT = Radiation Therapy 
a = Mean Survival V = vincristine E = Etoposide 
(VP 16-213) 







Radiation ^ ^ ^ 70 
Chemotherapy RT^ 8Z* ^ 255 
CAV + RT^86^ 400 
Patient Long-Term 
Characteristics Survivors 
All LD 0% LD 
All LD 5% LD 
+ 6% LD + ED 
100 LD 4% (LD + ED) 
300 ED 11% LD 
2% ED 
+ = Not Reported RT = Radiation Therapy 
C = cyclophosphamide A = Adriamycin (doxorubicin) 
V = vincristine 
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GROUP 2 * Extensive Disease 
cycle 
1 2 3 4 5 6 7 8 9 
Adri a A A A A A A A A 
Diagnosis CTX C C C C C C C C 
->/TVCR V V V V V V V V 
Elective 
Rad Rx Prophylactic 
j 
Whole Brain Rad 
CTX 
VCR 
Adri a A A A A 
CTX VP-16 C VP-16 C VP-16 C VP-16 C VP-16 
VCR V V V V 











Adria : Adriamycin 40 mg/m IV day 1 
2 
CTX : Cyclophosphamide 1000 mg/m IV day 1 
2 
VCR : Vincristine 1.4 mg/m IV day 1 (each dose limited to 2 mg total) 
VP-16 125 mg/m^ IV days 1, 3, 5 
Table 10 — Treatment Protocol for Extensive Disease 

CAV Therapy Patients n = 21 (54%) 
10 females: 11 males 
Median age (range): 59 years (49-71) 
Subgroup: CAV - Limited Disease Patients n = 8 (38%) 
P.S. 0 = 1-- 6 pts. fully am 
P.S. 1 = 5 -—- (75%) 
P.S. 2 = 0~___ 1 pt. not fully 
P.S. 3 = 1 ambulatory 
P.S. 4 = 0-— (12%) 
P.S. unknown = 1 
Subgroup: CAV - Extensive Disease Patients n = 13 (62%) 
P.S. 0 = 0- pts. fully ambulatory 
P.S. 1 = 8-" (62%) 
P.S. 2 = 4-____ 5 pts. not fully 
P.S. 3=0 ambulatory 
P.S. 4 = 1— (38%) 
CAV/E Therapy Patients n = 18 (46%) 
10 females: 8 males 
Median age (range): 66 years (53-72) 
Subgroup: CAV/E - Limited Disease Patients n = 7 (39%) 
P.S. 0=3 




5 pts. fully ambulatory 
(71%) 
2 pts. not fully 
ambulatory 
(29%) 
Subgroup: CAV/E - Extensive Disease Patients n = 11 (61%) 
P.S. 0 = i—- -—_____ 3 pts. fully ambulatory 
P.S. 1 = 2 ——- ' '— (27%) 
P.S. 2 = 4 —_____ 8 pts. not fully 
P.S. 3=3 ambulatory 
P.S. 4 = 1——' (73%) 
E = Etoposide (VP-16-213) 
A = Adriamycin (doxorubicin) 
C = cyclophosphamide 
V = vincristine 
Table 11 — Patient Characteristics by Treatment Arm 

96 
Number of pts % of ED pts 
with disease with disease Number of pts with 
at site+ at site this site as only 
involvement beyond 
Site CAV CAV/E CAV CAV/E primary tumor 
Liver 8 6 62% 55% 3 
Bone 7 5 54% 45% 1 
Bone Marrow 6 1 46% 9% 2 
Nodes (excluding chest) 3 2 23% 18% - 
Pleura 2* 2** 15% 18% - 
Bilateral Lung 1 1 8% 9% - 
Subcutaneous Nodules 2 - .5% - - 
Brain - 1 - 9% - 
Neither confirmed 1 by cytology + Total ED patients = 24 
'x"* 1 of 2 confirmed by cytology ED-CAV = 13 
ED-CAV/E = 11 
Table 12 — Metastatic Sites at Diagnosis in Extensive Disease (ED) 
Patients by Treatment Arm 

97 
Number of patients % of all patients who 
Site with relapse at site+ who relapsed , 
Chest (excluding pleura) 9 23% 
Liver 7 18% 
Bone 5 13% 
Brain 5 13% 
Nodes (excluding chest) 4 10% 
Pleura 2* 5% 
Bone Marrow 1 3% 
Subcutaneous Nodules 1 3% 
Others CNS (choroidal) 1 3% 
Neither confirmed by cytology; one recurrent +Total pts = 39 
Relapses at Sites of Initial Disease* 
Site Number of Relapses 
Liver 4 
Bone 3 
Nodes (excluding chest) 2 
Pleura 1 
* Excludes chest relapses, except in pleura 
Table 13 — Sites of Relapse 

98 
Response to Therapy by Stage and Treatment Arm 
All patients (n=39) (no.(%)) 
Limited Disease (n=15) 





CR PR NR 
15 (38%) 13 (33%) 11 (28%) 
12 (80%) 1 ( 7%) 2 (13%) 
3 (12%) 12 (50%) 9 (38%) 
7 (88%) 1 (12%) 0 
5 (71%) 0 2 (29%) 
2 (15%) 7 (54%) 4 (31%) 
1 ( 9%) 5 (45%) 5 (45%) 









LD = Limited-stage disease 
CR = Complete response 
NR = Non-responders 
C = cyclophosphamide 
V = vincristine 











ED = Extensive-stage disease 
PR = Partial response 
A = Adriamycin (doxorubicin) 
E = Etoposide (VP-16-213) 




LD - CR 

























LD = Limited-stage disease 
CR = Complete response 
NR = Non-responders 
C = cyclophosphamide 
V = vincristine 
ED = Extensive-stage disease 
PR = Partial response 
A = Adriamycin (doxorubicin) 
E = Etoposide (VP-16-213) 
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